Frequency of hippocampal formation atrophy in norma

Neurobiology of Aging 18, 1-11 DOI: 10.1016/s0197-4580(96)00213-8

Citation Report

#	Article	IF	CITATIONS
1	The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Neurology, 1991, 41, 479-479.	1.5	4,673
2	Cortisol Reduces Hippocampal Glucose Metabolism in Normal Elderly, but Not in Alzheimer's Disease*. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3251-3259.	1.8	134
3	Specific Hippocampal Volume Reductions in Individuals at Risk for Alzheimer's Disease. Neurobiology of Aging, 1997, 18, 131-138.	1.5	376
4	Neuropathological Staging of Alzheimer-Related Lesions: The Challenge of Establishing Relations to Age. Neurobiology of Aging, 1997, 18, 369-375.	1.5	12
5	Drug Treatment of Depression Associated with Dementia or Presented as †Pseudodementia' in Older Adults with Down Syndrome. Journal of Applied Research in Intellectual Disabilities, 1997, 10, 312-322.	1.3	22
6	Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neuroscience, 1998, 1, 69-73.	7.1	1,425
7	Alzheimer changes are common in aged drivers killed in single car crashes and at intersections. Forensic Science International, 1998, 96, 115-127.	1.3	22
8	Apolipoprotein-E deficiency results in an altered stress responsiveness in addition to an impaired spatial memory in young mice. Brain Research, 1998, 788, 151-159.	1.1	42
9	Tau in Alzheimer's disease. Trends in Cell Biology, 1998, 8, 425-427.	3.6	526
10	Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Annals of Neurology, 1998, 43, 303-310.	2.8	173
11	Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D Neurogenetics, 1998, 1, 223-228.	0.7	66
12	TGF-β receptors-I and -II immunoexpression in Alzheimer's disease: a comparison with aging and progressive supranuclear palsy. Neurobiology of Aging, 1998, 19, 527-533.	1.5	34
13	Progression of neurofibrillary changes and PHF-Ï,, in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology. Neurobiology of Aging, 1998, 19, 517-525.	1.5	67
14	Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Annals of Neurology, 1998, 44, 288-291.	2.8	257
15	Lewy Bodies Contain Altered α-Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes. American Journal of Pathology, 1998, 153, 1365-1370.	1.9	484
16	Clinicopathologic Studies in Cognitively Healthy Aging and Alzheimer Disease. Archives of Neurology, 1998, 55, 326.	4.9	630
17	Brain volume preserved in healthy elderly through the eleventh decade. Neurology, 1998, 51, 1555-1562.	1.5	138
18	Hippocampus and Parahippocampal Gyrus Linear Measurements Based on Magnetic Resonance in Alzheimer's Disease. European Neurology, 1998, 39, 16-25.	0.6	28

TION REI

	CITATION	CITATION REPORT	
#	Article	IF	CITATIONS
19	Neurofibrillary Tangles and Alzheimer's Disease. European Neurology, 1998, 40, 130-140.	0.6	138
20	Early diagnostic indices for the prevention of Alzheimer's disease. Annals of Medicine, 1998, 30, 553-559.	1.5	27
21	Spatial Analysis of the Neuronal Density of Aminergic Brainstem Nuclei in Primary Neurodegenerative and Vascular Dementia: A Comparative Immunocytochemical and Quantitative Study Using a Graph Method. Analytical Cellular Pathology, 1999, 19, 125-138.	2.1	15
22	Specific temporoparietal gyral atrophy reflects the pattern of language dissolution in Alzheimer's disease. Brain, 1999, 122, 675-686.	3.7	87
23	Neural Recruitment and Cognitive Aging: Two Hemispheres Are Better Than One, Especially as You Age. Psychological Science, 1999, 10, 494-500.	1.8	186
24	Magnetic Resonance Imaging-Based Hippocampal Volumetry in Patients with Dementia of the Alzheimer Type. Dementia and Geriatric Cognitive Disorders, 1999, 10, 284-288.	0.7	57
25	Biomarkers of Alzheimer Disease. Archives of Neurology, 1999, 56, 281.	4.9	91
26	Structural and functional brain asymmetries in human situs inversus totalis. Neurology, 1999, 53, 1260-1260.	1.5	207
27	The Hippocampus and Delayed Recall: Bigger is not Necessarily Better?. Memory, 1999, 7, 715-733.	0.9	64
28	Neurological Changes Induced by Stress in Streptozotocin Diabetic Rats. Annals of the New York Academy of Sciences, 1999, 893, 126-137.	1.8	77
29	Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology, 1999, 52, 1397-1397.	1.5	1,300
30	Early diagnosis of dementia: neuroimaging. Journal of Neurology, 1999, 246, 16-20.	1.8	100
32	Editorial: Useful URLs. Trends in Cell Biology, 1999, 9, 244.	3.6	0
33	Antibodies to ?-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Annals of Neurology, 1999, 45, 353-357.	2.8	289
34	Tangles and plaques in nondemented aging and ?preclinical? Alzheimer's disease. Annals of Neurology, 1999, 45, 358-368.	2.8	1,569
35	Stereological estimation of the total number of neurons in the murine hippocampus using the optical disector. , 1999, 408, 560-566.		71
36	Early diagnosis of Alzheimer dementia based on clinical and biological factors. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S3-S9.	1.8	45
37	Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5598-5603.	3.3	501

#	Article	IF	CITATIONS
38	Corticosteroids, the Aging Brain and Cognition. Trends in Endocrinology and Metabolism, 1999, 10, 92-96.	3.1	93
39	The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience, 1999, 95, 721-725.	1.1	369
40	Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease. FEBS Letters, 1999, 451, 39-44.	1.3	81
41	Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biological Psychiatry, 1999, 46, 1595-1602.	0.7	430
42	Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study. Psychological Medicine, 1999, 29, 181-187.	2.7	51
43	MRI Temporal Lobe Volume Measures and Neuropsychologic Function in Alzheimer's Disease. Journal of Neuroimaging, 1999, 9, 2-9.	1.0	49
44	Inheritance of the ApoE ε4 Allele Increases the Rate of Brain Atrophy in Dementia Patients. Dementia and Geriatric Cognitive Disorders, 1999, 10, 262-268.	0.7	31
45	Latent learning in medial temporal amnesia: Evidence for disrupted representational but preserved attentional processes Neuropsychology, 2000, 14, 3-15.	1.0	12
46	Association between Changes in Adrenal Secretion and Cerebral Morphometric Correlates in Normal Aging and Senile Dementia. Dementia and Geriatric Cognitive Disorders, 2000, 11, 90-99.	0.7	46
47	Contribution of neuroimaging to the differential diagnosis of dementias and other late life psychiatric disorders. Reviews in Clinical Gerontology, 2000, 10, 55-68.	0.5	1
48	Hemispheric differences in hippocampal volume predict verbal and spatial memory performance in patients with Alzheimer's disease. Hippocampus, 2000, 10, 136-142.	0.9	158
49	Alzheimer's Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 1-8.	0.9	174
51	Decreased thioredoxin and increased thioredoxin reductase levels in alzheimer's disease brain. Free Radical Biology and Medicine, 2000, 28, 418-427.	1.3	188
52	AIDS does not alter the total number of neurons in the hippocampal formation but induces cell atrophy: a stereological study. Acta Neuropathologica, 2000, 99, 643-653.	3.9	26
53	Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology, 2000, 54, 1760-1767.	1.5	356
54	Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 11050-11055.	3.3	4,968
55	Differential Effects of Aging on the Functions of the Corpus Callosum. Developmental Neuropsychology, 2000, 18, 113-137.	1.0	69
56	Effect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer Disease. Archives of Neurology, 2000, 57, 831.	4.9	69

#	Article	IF	CITATIONS
57	Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology, 2000, 55, 1854-1862.	1.5	150
58	"Preclinical―AD revisited. Neurology, 2000, 55, 370-376.	1.5	347
59	Expression of tau immunoreactivity in the spinal motor neurons of Alzheimer's disease. Neurology, 2000, 55, 1727-1730.	1.5	28
60	Glucose Hypometabolism and Neuropathological Correlates in Brains of Dementia with Lewy Bodies. Experimental Neurology, 2000, 162, 247-256.	2.0	185
61	Quantitative Volumetric Analyses of Brain Magnetic Resonance Imaging from Rat with Chronic Neuroinflammation. Experimental Neurology, 2000, 165, 347-354.	2.0	43
62	Specific downregulation of presenilin 2 gene expression is prominent during early stages of sporadic late-onset Alzheimer's disease. Molecular Brain Research, 2000, 78, 138-145.	2.5	19
63	MRI description of cerebral atrophy in mouse lemur primates. Neurobiology of Aging, 2000, 21, 81-88.	1.5	48
64	Age-related decline in water maze learning and memory in rats: strain differences. Neurobiology of Aging, 2000, 21, 671-681.	1.5	119
65	The relation between global and limbic brain volumes on MRI and cognitive performance in healthy individuals across the age range. Neurobiology of Aging, 2000, 21, 569-576.	1.5	123
66	Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets?. Neurobiology of Aging, 2000, 21, 441-445.	1.5	107
67	Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's diseaseâ~†. Neurobiology of Aging, 2000, 21, 19-26.	1.5	324
68	Autopsy in dementing disorders of the elderly. Current Diagnostic Pathology, 2000, 6, 181-191.	0.4	2
69	AGING, MILD COGNITIVE IMPAIRMENT, AND ALZHEIMER'S DISEASE. Neurologic Clinics, 2000, 18, 789-805.	0.8	116
70	β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity. Journal of Biological Chemistry, 2000, 275, 5626-5632.	1.6	720
71	One-year Age Changes in MRI Brain Volumes in Older Adults. Cerebral Cortex, 2000, 10, 464-472.	1.6	468
72	Clinical and Pathological Diagnosis of Frontotemporal Dementia. Archives of Neurology, 2001, 58, 1803.	4.9	1,381
73	Current Concepts in Mild Cognitive Impairment. Archives of Neurology, 2001, 58, 1985.	4.9	4,117
74	Oxidation of Aβ and Plaque Biogenesis in Alzheimer's Disease and Down Syndrome. Neurobiology of Disease, 2001, 8, 792-806.	2.1	71

#	Article	IF	CITATIONS
75	Hippocampal Apoptosis in Major Depression Is a Minor Event and Absent from Subareas at Risk for Glucocorticoid Overexposure. American Journal of Pathology, 2001, 158, 453-468.	1.9	255
76	FE65 in Alzheimer's Disease. American Journal of Pathology, 2001, 158, 1585-1591.	1.9	35
77	Automated Hippocampal Segmentation by Regional Fluid Registration of Serial MRI: Validation and Application in Alzheimer's Disease. NeuroImage, 2001, 13, 847-855.	2.1	124
78	Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiology of Aging, 2001, 22, 187-194.	1.5	410
79	Increased alpha 2-adrenergic receptor binding in locus coeruleus projection areas in dementia with Lewy bodies. Neurobiology of Aging, 2001, 22, 555-561.	1.5	30
80	MRI of human entorhinal cortex: a reliable protocol for volumetric measurement. Neurobiology of Aging, 2001, 22, 737-745.	1.5	74
81	MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease â~† â~†This research was supported by grants P01 AC09466 and P30 AC10161 from the National Institute on Aging, National Institutes of Health Neurobiology of Aging, 2001, 22, 747-754.	1.5	447
82	Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neuroscience Letters, 2001, 297, 97-100.	1.0	332
83	Natural history of Alzheimer's disease. Aging Clinical and Experimental Research, 2001, 13, 171-182.	1.4	49
84	Structural neuroimaging of Alzheimer's disease and other dementias. Aging Clinical and Experimental Research, 2001, 13, 203-209.	1.4	15
85	Henry M. Wisniewski M.D. Ph.D Journal of Alzheimer's Disease, 2001, 3, 7-22.	1.2	4
86	Effects of Transdermal Nicotine on Learning, Memory, Verbal Fluency, Concentration, and General Health in a Healthy Sample at Risk for Dementia. International Psychogeriatrics, 2001, 13, 465-475.	0.6	36
87	Canaries in a Coal Mine. Archives of General Psychiatry, 2001, 58, 859.	13.8	26
88	Correlation Between Cortical Î, Activity and Hippocampal Volumes in Health, Mild Cognitive Impairment, and Mild Dementia. Journal of Clinical Neurophysiology, 2001, 18, 178-184.	0.9	93
89	Brain Functional Imaging in Early and Preclinical Alzheimer's Disease. , 0, , 153-164.		4
90	Impact of Drugs and Alcohol on the Brain Through the Life Cycle. Journal of Social Work Practice in the Addictions, 2001, 1, 41-63.	0.4	12
91	Statistical aspects of quantitative image analysis of β-amyloid in the APPV717F transgenic mouse model of Alzheimer's disease. Journal of Neuroscience Methods, 2001, 108, 145-152.	1.3	15
92	Down syndrome and Alzheimer's disease: A link between development and aging. Mental Retardation and Developmental Disabilities Research Reviews, 2001, 7, 172-178.	3.5	260

#	Article	IF	CITATIONS
93	Selective Loss of KGDHC-Enriched Neurons in Alzheimer Temporal Cortex. Journal of Molecular Neuroscience, 2001, 17, 361-370.	1.1	46
94	Altered subcellular distribution of transcriptional regulators in response to Aβ peptide and during Alzheimer's disease. Mechanisms of Ageing and Development, 2001, 123, 11-20.	2.2	40
95	α-Synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. Brain Research, 2001, 888, 287-296.	1.1	148
96	Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease. Archives of Neurology, 2001, 58, 1395.	4.9	509
97	Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy in Dementias. Journal of Geriatric Psychiatry and Neurology, 2001, 14, 145-166.	1.2	39
98	Differing patterns of temporal atrophy in Alzheimer's disease and semantic dementia. Neurology, 2001, 57, 216-225.	1.5	537
99	Intron-Exon Swapping of Transglutaminase mRNA and Neuronal Tau Aggregation in Alzheimer's Disease. Journal of Biological Chemistry, 2001, 276, 3295-3301.	1.6	99
100	Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology, 2001, 56, 820-823.	1.5	130
101	Neuropathological Correlates of Dysarthria in Progressive Supranuclear Palsy. Archives of Neurology, 2001, 58, 265.	4.9	48
102	Relationship between Discrimination Tasks of the Cantab and the Corpus Callosum Morphology in Alzheimer's Disease. Perceptual and Motor Skills, 2001, 92, 1205-1210.	0.6	4
103	Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 165-173.	0.9	171
104	Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 483-488.	0.9	115
105	Recovery and Expression of Messenger RNA from Postmortem Human Brain Tissue. Modern Pathology, 2001, 14, 1157-1161.	2.9	63
106	Practice parameter: Management of dementia (an evidence-based review) [RETIRED]. Neurology, 2001, 56, 1154-1166.	1.5	1,165
107	Practice parameter: Diagnosis of dementia (an evidence-based review). Neurology, 2001, 56, 1143-1153.	1.5	1,400
108	Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology, 2002, 58, 1791-1800.	1.5	2,555
109	Patients with vascular dementia due to microvascular pathology have significant hippocampal neuronal loss. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 747-751.	0.9	116
110	Clinicopathological Validation Study of Four Sets of Clinical Criteria for Vascular Dementia. American Journal of Psychiatry, 2002, 159, 82-87.	4.0	193

#	Article	IF	CITATIONS
111	Clinical and Neuropathological Characteristics of Hippocampal Sclerosis. Archives of Neurology, 2002, 59, 1099.	4.9	136
112	Brain function and cognition in a community sample of elderly Latinos. Neurology, 2002, 59, 378-383.	1.5	73
113	Hippocampal volume as an index of Alzheimer neuropathology. Neurology, 2002, 58, 1476-1482.	1.5	308
114	Minimal hippocampal width relates to plasma homocysteine in community-dwelling older people. Age and Ageing, 2002, 31, 440-444.	0.7	79
115	β-Secretase Protein and Activity Are Increased in the Neocortex in Alzheimer Disease. Archives of Neurology, 2002, 59, 1381.	4.9	656
116	Cognitive Deficits and Polymorphism of Apolipoprotein E in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2002, 13, 171-177.	0.7	8
117	Eyeblink Classical Conditioning in Aging Animals. , 2002, , 155-178.		0
118	Brain structure and cognition in a community sample of elderly Latinos. Neurology, 2002, 59, 383-391.	1.5	109
119	Tau Conformational Changes Correspond to Impairments of Episodic Memory in Mild Cognitive Impairment and Alzheimer's Disease. Experimental Neurology, 2002, 177, 475-493.	2.0	167
120	Insights into Aβ and Presenilin from a Canine Model of Human Brain Aging. Neurobiology of Disease, 2002, 9, 1-10.	2.1	33
121	Severe involvement of the ambient gyrus in a case of dementia with argyrophilic grain disease. Journal of the Neurological Sciences, 2002, 196, 71-75.	0.3	19
122	The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. Journal of the Neurological Sciences, 2002, 203-204, 131-136.	0.3	55
123	Inherited dementias. Neurologic Clinics, 2002, 20, 779-808.	0.8	12
124	Magnetization Transfer Ratio in Mild Cognitive Impairment and Dementia of Alzheimer's Type. NeuroImage, 2002, 15, 604-610.	2.1	95
125	Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochemistry International, 2002, 40, 69-78.	1.9	126
126	Cerebellar diffuse amyloid plaques are derived from dendritic AÎ ² 42 accumulations in Purkinje cells. Neurobiology of Aging, 2002, 23, 213-223.	1.5	80
127	Use of bomb pulse carbon-14 to age senile plaques and neurofibrillary tangles in Alzheimer's disease. Neurobiology of Aging, 2002, 23, 179-186.	1.5	30
128	Aβ as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiology of Aging, 2002, 23, 1051-1072.	1.5	140

#	Article	IF	CITATIONS
129	Blood and CSF biomarkers for AD revisited: what's new, what's good, and is this where we should be looking?. Neurobiology of Aging, 2002, 23, 517-519.	1.5	9
130	Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. Neurobiology of Aging, 2002, 23, 1077-1084.	1.5	54
131	Altered performance characteristics in cognitive tasks: comparison of the albino ICR and CD1 mouse strains. Behavioural Brain Research, 2002, 133, 351-361.	1.2	52
132	Neuropsychology of Cognitive Disorders. , 0, , 309-334.		0
133	Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacology Biochemistry and Behavior, 2002, 71, 119-138.	1.3	59
134	Relationship between attentional performance and corpus callosum morphometry in patients with Alzheimer's disease. Neuropsychologia, 2002, 40, 946-956.	0.7	22
135	Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurology, The, 2002, 1, 13-21.	4.9	337
136	Proteomic identification of oxidatively modified proteins in alzheimer's disease brain. part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radical Biology and Medicine, 2002, 33, 562-571.	1.3	545
137	Persistent cognitive impairment following surgical treatment of Cushing's syndrome. Psychoneuroendocrinology, 2002, 27, 367-383.	1.3	122
138	Salivary cortisol day profiles in elderly with mild cognitive impairment. Psychoneuroendocrinology, 2002, 27, 777-789.	1.3	62
139	Age-related changes in source memory retrieval: an ERP replication and extension. Cognitive Brain Research, 2002, 13, 323-338.	3.3	78
140	Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Annals of Neurology, 2002, 51, 145-155.	2.8	639
141	Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Annals of Neurology, 2002, 52, 205-210.	2.8	300
142	Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer's disease. Journal of Neuroscience Research, 2002, 70, 451-461.	1.3	105
143	Parkinson's disease and dementia with Lewy bodies: One disease or two?. Movement Disorders, 2002, 17, 1161-1165.	2.2	69
144	Senile plaques do not induce susceptibility effects inT2*-weighted MR microscopic images. NMR in Biomedicine, 2002, 15, 197-203.	1.6	70
146	Stage-dependent and sector-specific neuronal loss in hippocampus during Alzheimer's disease. Acta Neuropathologica, 2002, 103, 363-369.	3.9	152
147	Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus. Acta Neuropathologica, 2002, 104, 471-481.	3.9	77

#	Article	IF	CITATIONS
148	Quantification of neurons in Alzheimer and control brains with ex vivo high resolution magic angle spinning proton magnetic resonance spectroscopy and stereology. Magnetic Resonance Imaging, 2002, 20, 527-533.	1.0	75
149	Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1473-1480.	3.3	80
150	Decreased estrogen receptor-? expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer patients. Acta Neuropathologica, 2003, 106, 213-220.	3.9	54
151	Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathologica, 2003, 106, 374-382.	3.9	105
152	Neurofibrillary degeneration of the Alzheimer-type: an alternate pathway to neuronal apoptosis?. Biochemical Pharmacology, 2003, 66, 1619-1625.	2.0	45
153	Age-related differences in the functional connectivity of the hippocampus during memory encoding. Hippocampus, 2003, 13, 572-586.	0.9	233
154	Anatamopathological spectrum of tauopathies. Movement Disorders, 2003, 18, 13-20.	2.2	20
155	Association ofHFE mutations with neurodegeneration and oxidative stress in Alzheimer's disease and correlation withAPOE. American Journal of Medical Genetics Part A, 2003, 119B, 48-53.	2.4	82
156	Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Annals of Neurology, 2003, 54, 393-398.	2.8	95
157	Cognitive deficits in preclinical Alzheimer's disease. Acta Neurologica Scandinavica, 2003, 107, 29-33.	1.0	79
158	Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Medicine, 2003, 9, 448-452.	15.2	1,423
159	Improvement in learning associated with increase in hippocampal formation volume. Biological Psychiatry, 2003, 53, 233-238.	0.7	140
160	Pathological heterogeneity of clinically diagnosed corticobasal degeneration. Journal of the Neurological Sciences, 2003, 216, 127-134.	0.3	81
161	Dissociating Hippocampal versus Basal Ganglia Contributions to Learning and Transfer. Journal of Cognitive Neuroscience, 2003, 15, 185-193.	1.1	184
162	2-dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease. Molecular Imaging and Biology, 2003, 5, 404-417.	1.3	98
163	Subicular Dendritic Arborization in Alzheimer's Disease Correlates with Neurofibrillary Tangle Density. American Journal of Pathology, 2003, 163, 1615-1621.	1.9	76
164	On the Involvement of Prefrontal Networks in Cognitive Ageing. Cortex, 2003, 39, 1107-1128.	1.1	228
165	A grading system of Alzheimer disease lesions in neocortical areas. Neurobiology of Aging, 2003, 24,	1.5	50

#	Article	IF	CITATIONS
166	Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease. Neurobiology of Aging, 2003, 24, 655-662.	1.5	57
167	Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. Journal of Chemical Neuroanatomy, 2003, 26, 233-242.	1.0	266
168	Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clinics of North America, 2003, 13, 197-209.	0.5	193
169	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clinics of North America, 2003, 13, 781-789.	0.5	74
170	Dietary Lipids in the Aetiology of Alzheimer???s Disease. Drugs and Aging, 2003, 20, 399-418.	1.3	36
171	Familial Dementia with Lewy Bodies with an Atypical Clinical Presentation. Journal of Geriatric Psychiatry and Neurology, 2003, 16, 59-64.	1.2	27
172	Results of a high-resolution genome screen of 437 Alzheimer's Disease families. Human Molecular Genetics, 2003, 12, 23-32.	1.4	304
173	Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 2003, 61, 304-309.	1.5	522
174	Lewy body cortical involvement may not always predict dementia in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 852-856.	0.9	176
175	Biochemical Diagnosis of Alzheimer Disease by Measuring the Cerebrospinal Fluid Ratio of Phosphorylated tau Protein to β-Amyloid Peptide42. Archives of Neurology, 2003, 60, 1202-6.	4.9	174
176	Dietary Fats and the Risk of Incident Alzheimer Disease. Archives of Neurology, 2003, 60, 194.	4.9	436
177	Decreased β-Amyloid1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease. JAMA - Journal of the American Medical Association, 2003, 289, 2094-103.	3.8	579
178	Genetic background regulates Â-amyloid precursor protein processing and Â-amyloid deposition in the mouse. Human Molecular Genetics, 2003, 12, 2949-2956.	1.4	82
179	Ageâ€Related Decline in Spatial Learning and Memory: Attenuation by Captopril. Clinical and Experimental Hypertension, 2003, 25, 455-474.	0.5	45
180	Regional Brain Atrophy Rate Predicts Future Cognitive Decline: 6-year Longitudinal MR Imaging Study of Normal Aging. Radiology, 2003, 229, 691-696.	3.6	253
181	The role of volumetric MRI in understanding mild cognitive impairment and similar classifications. Aging and Mental Health, 2003, 7, 238-250.	1.5	50
182	Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future. Radiology, 2003, 226, 315-336.	3.6	372
183	Parallel Compensatory and Pathological Events Associated with Tau Pathology in Middle Aged Individuals with Down Syndrome. Journal of Neuropathology and Experimental Neurology, 2003, 62, 917-926.	0.9	33

#	Article	IF	CITATIONS
184	Structural Magnetic Resonance Imaging in Established and Prodromal Alzheimer Disease: A Review. Alzheimer Disease and Associated Disorders, 2003, 17, 177-195.	0.6	88
185	Psychiatric Symptomatology and Prodromal Alzheimer's Disease. Alzheimer Disease and Associated Disorders, 2003, 17, 1-8.	0.6	104
186	Atrophy rate in medial temporal lobe during progression of Alzheimer disease. Neurology, 2004, 63, 2354-2359.	1.5	74
187	The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 2004, 62, 1984-1989.	1.5	403
188	Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4210-4215.	3.3	121
189	Alzheimer disease without neocortical neurofibrillary tangles. Neurology, 2004, 62, 1141-1147.	1.5	54
190	Combining Correlated Diagnostic Tests: Application to Neuropathologic Diagnosis of Alzheimer's Disease. Medical Decision Making, 2004, 24, 659-669.	1.2	27
191	Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease. Archives of Neurology, 2004, 61, 1044-53.	4.9	446
192	Isolated Executive Impairment and Associated Frontal Neuropathology. Dementia and Geriatric Cognitive Disorders, 2004, 17, 360-367.	0.7	27
193	Pathology and Neurotransmitter Abnormalities of Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2004, 17, 3-14.	0.7	62
194	Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurological Research, 2004, 26, 525-539.	0.6	154
195	Right prosubiculum amyloid plaque density correlates with anosognosia in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1396-1400.	0.9	37
196	Hippocampal size and memory function in the ninth and tenth decades of life: the Sydney Older Persons Study. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 548-554.	0.9	49
197	Cortical Lewy body disease. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 175-178.	0.9	15
198	Neuropathological diagnostic criteria for Alzheimer's disease. Neuropathology, 2004, 24, 254-260.	0.7	80
199	MRI and CSF studies in the early diagnosis of Alzheimer's disease. Journal of Internal Medicine, 2004, 256, 205-223.	2.7	185
200	EEG findings in dementia with Lewy bodies causing diagnostic confusion with sporadic Creutzfeldt-Jakob disease. European Journal of Neurology, 2004, 11, 838-841.	1.7	40
201	Effect of Vascular Lesions on Cognition in Alzheimer's Disease: A Community-Based Study. Journal of the American Geriatrics Society, 2004, 52, 1442-1448.	1.3	107

#	Article	IF	CITATIONS
202	Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Research, 2004, 1000, 1-7.	1.1	199
203	Overexpression of the human β-amyloid precursor protein downregulates cortistatin mRNA in PDAPP mice. Brain Research, 2004, 1023, 157-162.	1.1	13
204	In vivo amyloid imaging in Alzheimer?s disease. Neuroradiology, 2004, 46, 93-104.	1.1	52
205	Clinicopathological correlates in frontotemporal dementia. Annals of Neurology, 2004, 56, 399-406.	2.8	549
206	Reduction of cortical TrkA but not p75NTR protein in early-stage Alzheimer's disease. Annals of Neurology, 2004, 56, 520-531.	2.8	181
207	Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease. Expert Review of Neurotherapeutics, 2004, 4, 831-849.	1.4	41
208	Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology, 2004, 63, 1168-1174.	1.5	554
209	Dynamic Mapping of Alzheimer's Disease. Research and Perspectives in Alzheimer's Disease, 2004, , 87-112.	0.1	1
210	Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology. Journal of the Neurological Sciences, 2004, 225, 39-49.	0.3	55
211	Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. NeuroRx, 2004, 1, 196-205.	6.0	80
212	Familial Occurrence of Dementia With Lewy Bodies. American Journal of Geriatric Psychiatry, 2004, 12, 179-188.	0.6	30
213	Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Experimental Neurology, 2004, 190, 192-203.	2.0	358
214	So what if tangles precede plaques?. Neurobiology of Aging, 2004, 25, 721-723.	1.5	31
215	Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. Neurobiology of Aging, 2004, 25, 685-691.	1.5	75
216	Expression of the Small Heat-Shock Protein αB-Crystallin in Tauopathies with Glial Pathology. American Journal of Pathology, 2004, 164, 155-166.	1.9	112
217	Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiology of Disease, 2004, 15, 115-119.	2.1	33
218	Relationship between hippocampal volume and CA1 neuron loss in brains of humans with and without Alzheimer's disease. Neuroscience Letters, 2004, 361, 9-12.	1.0	53
219	Impaired conditioned taste aversion learning in APP transgenic mice. Neurobiology of Aging, 2004, 25, 1213-1219.	1.5	49

ARTICLE IF CITATIONS # Mild cognitive impairment: new neuropsychological and pharmacological target. Archives of Clinical 220 0.3 10 Neuropsychology, 2004, 19, 11-27. Morphological classification of brains via high-dimensional shape transformations and machine 221 2.1 304 learning methods. NeuroImage, 2004, 21, 46-57. 222 Functional Imaging in Healthy Aging and Alzheimer's Disease., 2004, 34, 62-95. 0 Lewy Body-Related α-Synucleinopathy in Aging. Journal of Neuropathology and Experimental Neurology, 2004, 63, 742-749. Unique Tauopathy in Fukuyama-Type Congenital Muscular Dystrophy. Journal of Neuropathology and 224 0.9 9 Experimental Neurology, 2005, 64, 1118-1126. A Comparison of the Addenbrooke's Cognitive Examination (ACE), Conventional Neuropsychological Assessment, and Simple MRI-Based Medial Temporal Lobe Evaluation in the Early Diagnosis of Alzheimer's Disease. Cognitive and Behavioral Neurology, 2005, 18, 144-150. Changes of Magnetic Resonance Imaging on the Brain in Beagle Dogs with Aging. Journal of Veterinary 226 0.3 53 Medical Science, 2005, 67, 961-967. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. 1.5 4,604 Neurology, 2005, 65, 1863-1872. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. Journal of 228 2.1 417 Neurochemistry, 2005, 93, 953-962. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. Journal of Neurochemistry, 2005, 93, 229 2.1 614 1412-1421. The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. Neuropathology and Applied Neurobiology, 2005, 230 1.8 60 31, 270-279. The expression of calcium/calmodulin-dependent protein kinase II- $1\pm$ in the hippocampus of patients with 1.1 Alzheimer's disease and its links with AD-related pathology. Brain Research, 2005, 1031, 101-108. Genetically engineered livestock: closer than we think?. Trends in Biotechnology, 2005, 23, 533-535. 232 4.9 15 En route to early diagnosis of Alzheimer's disease – are we there yet?. Trends in Biotechnology, 2005, 23, 531-533. 23 Absence of hippocampal volume differences in survivors of the Nazi Holocaust with and without 234 0.9 89 posttraumatic stress disorder. Psychiatry Research - Neuroimaging, 2005, 139, 53-64. Antemortem diagnosis of frontotemporal lobar degeneration. Annals of Neurology, 2005, 57, 480-488. 181 Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Annals of 236 2.8 264 Neurology, 2005, 58, 730-735. Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. Annals of 2.8 Neurology, 2005, 58, 773-776.

#	Article	IF	CITATIONS
238	Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration. Movement Disorders, 2005, 20, 34-39.	2.2	22
239	Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Movement Disorders, 2005, 20, 982-988.	2.2	111
240	Brain glucose metabolism in the early and specific diagnosis of Alzheimer?s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 486-510.	3.3	744
242	Apolipoprotein E co-localizes with newly formed amyloid β-protein (Aβ) deposits lacking immunoreactivity against N-terminal epitopes of Aβ in a genotype-dependent manner. Acta Neuropathologica, 2005, 110, 459-471.	3.9	50
243	Alterations in zinc transporter protein-1 (ZnT-1) in the brain of subjects with mild cognitive impairment, early, and late-stage alzheimer's disease. Neurotoxicity Research, 2005, 7, 265-271.	1.3	82
244	Problems Associated with Biological Markers of Alzheimer's Disease. Neurochemical Research, 2005, 30, 1501-1510.	1.6	34
245	Effects of Healthy Aging on Hippocampal and Rhinal Memory Functions: An Event-Related fMRI Study. Cerebral Cortex, 2005, 16, 1771-1782.	1.6	327
246	MRI predictors of risk of incident Alzheimer disease: A longitudinal study. Neurology, 2005, 64, 1520-1524.	1.5	185
247	Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology, 2005, 64, 1152-1156.	1.5	488
248	Age does not increase rate of forgetting over weeks—Neuroanatomical volumes and visual memory across the adult life-span. Journal of the International Neuropsychological Society, 2005, 11, 2-15.	1.2	30
250	Most cases of dementia with hippocampal sclerosis may represent frontotemporal dementia. Neurology, 2005, 64, 1102-1102.	1.5	33
251	Environmental reduplicative paramnesia in a case of atypical Alzheimer's disease. Neurocase, 2005, 11, 216-226.	0.2	13
252	The evolution and pathology of frontotemporal dementia. Brain, 2005, 128, 1996-2005.	3.7	585
253	A stochastic model for studying the laminar structure of cortex from MRI. IEEE Transactions on Medical Imaging, 2005, 24, 728-742.	5.4	17
254	Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology, 2005, 64, 834-841.	1.5	490
255	Changing Patient Characteristics and Survival Experience in an Alzheimer's Center Patient Cohort. Dementia and Geriatric Cognitive Disorders, 2005, 20, 198-208.	0.7	52
256	Cognitive aging and Alzheimer's disease. Postgraduate Medical Journal, 2005, 81, 343-352.	0.9	29
257	Alzheimers Disease and Non-Steroidal Anti-Inflammatory Drugs: Old Therapeutic Tools with Novel Mechanisms of Action?. Current Medicinal Chemistry - Central Nervous System Agents, 2005, 5, 111-117.	0.6	2

#	Article	IF	CITATIONS
258	Physicochemical characteristics of soluble oligomeric Aβand their pathologic role in Alzheimer's disease. Neurological Research, 2005, 27, 869-881.	0.6	113
259	Relating Medial Temporal Lobe Volume to Frontal fMRI Activation for Memory Encoding in Older Adults. Cortex, 2005, 41, 595-602.	1.1	28
260	The Role of Quantitative Structural Imaging in the Early Diagnosis of Alzheimer's DiseaseQ4. Neuroimaging Clinics of North America, 2005, 15, 803-826.	0.5	39
261	Disturbance of Endogenous Circadian Rhythm in Aging and Alzheimer Disease. American Journal of Geriatric Psychiatry, 2005, 13, 359-368.	0.6	152
262	From The Cover: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2273-2276.	3.3	790
263	Relationship between Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2005, 11, 305-309.	1.1	17
264	Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead. Neurobiology of Aging, 2005, 26, 581-583.	1.5	35
265	Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx, 2005, 2, 348-360.	6.0	138
266	Distribution of brain atrophy in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 2005, 232, 83-90.	0.3	78
267	Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory. Journal of Neuroscience, 2005, 25, 7709-7717.	1.7	1,839
268	Neuropathology of Alzheimer's Disease. Neuroimaging Clinics of North America, 2005, 15, 755-765.	0.5	64
269	Management of Parkinson???s Disease Dementia. Drugs and Aging, 2006, 23, 807-822.	1.3	19
271	Smooth functional and structural maps on the neocortex via orthonormal bases of the Laplace-Beltrami operator. IEEE Transactions on Medical Imaging, 2006, 25, 1296-1306.	5.4	124
272	??-Secretase Inhibitors for Alzheimer??s Disease. Drugs in R and D, 2006, 7, 87-97.	1.1	113
273	Convergence of Heat Shock Protein 90 with Ubiquitin in Filamentous α-Synuclein Inclusions of α-Synucleinopathies. American Journal of Pathology, 2006, 168, 947-961.	1.9	154
274	Pathological Heterogeneity of Frontotemporal Lobar Degeneration with Ubiquitin-Positive Inclusions Delineated by Ubiquitin Immunohistochemistry and Novel Monoclonal Antibodies. American Journal of Pathology, 2006, 169, 1343-1352.	1.9	296
275	Intervenciones en deterioro cognitivo grave. Revista Espanola De Geriatria Y Gerontologia, 2006, 41, 42-48.	0.2	1
276	Mild Cognitive Impairment and Dementia. Annual Review of Clinical Psychology, 2006, 2, 379-388.	6.3	46

#	Article	IF	CITATIONS
277	Comparison of clinical and neuropathologic diagnoses of Alzheimer's disease in 3 epidemiologic samples. , 2006, 2, 2-11.		42
278	Body mass index in older persons is associated with Alzheimer disease pathology. Neurology, 2006, 67, 1949-1954.	1.5	112
279	Alzheimer neuropathology in nondemented aging: Keeping mind over matter. Neurology, 2006, 66, 1801-1802.	1.5	10
280	Lack of association of two chromosome 10q24 SNPs with Alzheimer's disease. Neuroscience Letters, 2006, 408, 170-172.	1.0	5
281	Brain pathology and neuronal losses in the living brain of Alzheimer's patients. International Congress Series, 2006, 1290, 150-155.	0.2	3
282	Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 field in Alzheimer's disease. Neurobiology of Aging, 2006, 27, 270-277.	1.5	80
283	Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiology of Aging, 2006, 27, 387-393.	1.5	31
284	Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem brain. Neurobiology of Aging, 2006, 27, 909-917.	1.5	49
285	Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease. Neurobiology of Aging, 2006, 27, 1554-1563.	1.5	146
286	Altered expression of zinc transporters-4 and -6 in mild cognitive impairment, early and late Alzheimer's disease brain. Neuroscience, 2006, 140, 879-888.	1.1	91
287	Physiopathologie de la maladie d'Alzheimer. EMC - Traité De Médecine AKOS, 2006, 1, 1-11.	0.0	0
288	Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. Journal of the International Neuropsychological Society, 2006, 12, 707-735.	1.2	210
289	β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics, 2006, 6, 6566-6577.	1.3	62
290	Quantitative analysis of neurofibrillary pathology in a general population to reappraise neuropathological criteria for senile dementia of the neurofibrillary tangle type (tangle-only) Tj ETQq1 1 0.784314	4 ngBT ∕Ov	verbosck 10 Tf
291	Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using αâ€6ynuclein Immunohistochemistry. Brain Pathology, 2000, 10, 378-384.	2.1	612
292	Excitatory Amino Acid Transporter EAATâ€2 in Tangleâ€bearing Neurons in Alzheimer's Disease. Brain Pathology, 2002, 12, 405-411.	2.1	43
293	From Healthy Aging to Early Alzheimer's Disease: <i>In Vivo</i> Detection of Entorhinal Cortex Atrophy. Annals of the New York Academy of Sciences, 2000, 911, 240-253.	1.8	188
294	Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study. Neuropathology and Applied Neurobiology, 2006, 32, 492-504.	1.8	29

щ		15	CITATIONS
#	ARTICLE	IF	CITATIONS
295	Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathologica, 2006, 111, 503-509.	3.9	127
296	RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathologica, 2006, 112, 405-415.	3.9	427
297	Predicting memory performance in normal ageing using different measures of hippocampal size. Neuroradiology, 2006, 48, 90-99.	1.1	21
298	Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 210-221.	3.3	75
299	Neuroglia in the inferior olivary nucleus during normal aging and Alzheimer's disease. Journal of Cellular and Molecular Medicine, 2006, 10, 145-156.	1.6	17
300	Apolipoprotein E variants and cognition in healthy individuals: A critical opinion. Brain Research Reviews, 2006, 51, 125-135.	9.1	37
301	Adiposity indices and dementia. Lancet Neurology, The, 2006, 5, 713-720.	4.9	203
302	Coxibs and Alzheimer's disease: Should they stay or should they go?. Annals of Neurology, 2006, 59, 219-228.	2.8	51
303	Frontotemporal dementia: Clinicopathological correlations. Annals of Neurology, 2006, 59, 952-962.	2.8	444
304	Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Annals of Neurology, 2006, 60, 677-687.	2.8	236
305	Early frontotemporal dementia targets neurons unique to apes and humans. Annals of Neurology, 2006, 60, 660-667.	2.8	291
306	What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?. Brain, 2006, 129, 729-735.	3.7	235
307	Computational Models of the Hippocampal Region: Implications for Prediction of Risk for Alzheimers Disease in Non-demented Elderly. Current Alzheimer Research, 2006, 3, 247-257.	0.7	17
308	Memory complaints are related to Alzheimer disease pathology in older persons. Neurology, 2006, 67, 1581-1585.	1.5	172
309	Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 195-201.	1.2	20
310	Clinical phenotype of Parkinson disease dementia. Neurology, 2006, 67, 1605-1611.	1.5	222
311	Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity. Neurology, 2006, 67, 1984-1989.	1.5	87
312	Mild Cognitive Impairment Is Early-Stage Alzheimer Disease. Archives of Neurology, 2006, 63, 15.	4.9	160

#	Article	IF	Citations
313	Galanin Fiber Hypertrophy within the Cholinergic Nucleus Basalis during the Progression of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2006, 21, 205-214.	0.7	40
314	Neuropsychological Markers of Progression From Mild Cognitive Impairment to Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2006, 21, 189-196.	0.9	28
315	The Role of Functional Neuroimaging in Mild Cognitive Impairment. Current Medical Imaging, 2006, 2, 237-246.	0.4	1
316	Increased Neurofibrillary Tangles in the Brains of Older Pedestrians Killed in Traffic Accidents. Dementia and Geriatric Cognitive Disorders, 2006, 22, 20-26.	0.7	19
317	CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain, 2006, 129, 3035-3041.	3.7	541
318	DNA Oxidation in Alzheimer's Disease. Antioxidants and Redox Signaling, 2006, 8, 2039-2045.	2.5	133
319	Comparison of 18F-FDG PET and Optimized Voxel-Based Morphometry for Detection of Alzheimer's Disease: Aging Effect on Diagnostic Performance. Journal of Nuclear Medicine, 2007, 48, 1961-1970.	2.8	56
320	Altered Expression of COX-2 in Subdivisions of the Hippocampus during Aging and in Alzheimer's Disease: The Hisayama Study. Dementia and Geriatric Cognitive Disorders, 2007, 23, 423-431.	0.7	38
321	Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology, 2007, 68, 828-836.	1.5	649
322	TDP-43 Pathologic Lesions and Clinical Phenotype in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions. Archives of Neurology, 2007, 64, 1449.	4.9	61
323	Cortical biochemistry in MCI and Alzheimer disease: Lack of correlation with clinical diagnosis. Neurology, 2007, 68, 757-763.	1.5	54
324	Clinical and Psychometric Distinction of Frontotemporal and Alzheimer Dementias. Archives of Neurology, 2007, 64, 535.	4.9	66
325	Early-Onset Alzheimer's Disease Is Associated With Greater Pathologic Burden. Journal of Geriatric Psychiatry and Neurology, 2007, 20, 29-33.	1.2	108
326	What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?. Neurology, 2007, 69, 871-877.	1.5	271
327	Neuropsychological Comparison of Alzheimer's Disease and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2007, 23, 120-125.	0.7	42
328	Clinical Characteristics of Dementia Associated with Argyrophilic Grain Disease. Dementia and Geriatric Cognitive Disorders, 2007, 24, 229-234.	0.7	14
329	Direct and Indirect Measurement of Temporal Horn Volume and Temporal Horn Index and its Neuropsychological Correlation in Mild Cognitive Impaired and Alzheimer Diseased Patients. Current Medical Imaging, 2007, 3, 242-248.	0.4	2
330	Atlas of Alzheimer's Disease. , 0, , .		7

#	Article	IF	CITATIONS
331	Education delays accelerated decline on a memory test in persons who develop dementia. Neurology, 2007, 69, 1657-1664.	1.5	209
332	Longitudinal MRI and cognitive change in healthy elderly Neuropsychology, 2007, 21, 412-418.	1.0	233
333	Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Medicine, 2007, 8, 60-64.	0.8	153
334	Validation of clinical criteria for possible vascular dementia in the oldest-old. Neurobiology of Aging, 2007, 28, 579-585.	1.5	28
335	A TAP2 genotype associated with Alzheimer's disease in APOE4 carriers. Neurobiology of Aging, 2007, 28, 519-523.	1.5	29
336	ls aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?. Neurobiology of Aging, 2007, 28, 1465-1480.	1.5	124
337	Hippocampal sclerosis in tau-negative frontotemporal lobar degeneration. Neurobiology of Aging, 2007, 28, 1718-1722.	1.5	47
338	The enigma of mixed dementia. , 2007, 3, 40-53.		111
339	A chapter in the development of Alzheimer's disease research: A case study of public policies on the development and funding of research programs. , 2007, 3, 243-258.		19
340	Hippocampal shape analysis in Alzheimer's disease: A population-based study. NeuroImage, 2007, 36, 8-18.	2.1	101
341	TDP-43 in Familial and Sporadic Frontotemporal Lobar Degeneration with Ubiquitin Inclusions. American Journal of Pathology, 2007, 171, 227-240.	1.9	446
342	Redox-reactive autoantibodies in Alzheimer's patients' cerebrospinal fluids: Preliminary studies. Autoimmunity, 2007, 40, 390-396.	1.2	11
343	FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain, 2007, 130, 2616-2635.	3.7	508
344			
544	Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology, 2007, 69, 2197-2204.	1.5	1,513
345	Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology, 2007, 69, 2197-2204. Alzheimer's Disease and Mild Cognitive Impairment. Neurologic Clinics, 2007, 25, 577-609.	1.5 0.8	1,513 252
	Neurology, 2007, 69, 2197-2204.		
345	Neurology, 2007, 69, 2197-2204. Alzheimer's Disease and Mild Cognitive Impairment. Neurologic Clinics, 2007, 25, 577-609. Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: Similarities with Alzheimer's disease. Journal of the Neurological Sciences, 2007,	0.8	252

#	Article	IF	CITATIONS
349	Neuronal Intranuclear and Neuropil Inclusions for Pathological Assessment of Huntington?s Disease. Brain Pathology, 2007, 17, 31-37.	2.1	28
350	Lewy body variant of Alzheimer's disease or cerebral type Lewy body disease? Two autopsy cases of presenile onset with minimal involvement of the brainstem. Neuropathology, 2007, 27, 21-35.	0.7	25
351	Neuropathology of mild cognitive impairment. Neuropathology, 2007, 27, 578-584.	0.7	80
352	Stereological analysis of neuropil threads in the hippocampal formation: relationships with Alzheimer's disease neuronal pathology and cognition. Neuropathology and Applied Neurobiology, 2007, 33, 334-343.	1.8	25
353	Proposed neuropathological criteria for the <i>post mortem</i> diagnosis of multiple system atrophy. Neuropathology and Applied Neurobiology, 2007, 33, 615-620.	1.8	278
354	Clinical profiles of autopsy-confirmed dementia with Lewy bodies at institutionalization: Comparison with Alzheimer?s disease. Psychogeriatrics, 2007, 7, 98-103.	0.6	7
355	Early detection of Alzheimer's disease using neuroimaging. Experimental Gerontology, 2007, 42, 129-138.	1.2	140
356	Occludin is overexpressed in Alzheimer's disease and vascular dementia. Journal of Cellular and Molecular Medicine, 2007, 11, 569-579.	1.6	50
357	Hippocampal volume in aging combat veterans with and without post-traumatic stress disorder: Relation to risk and resilience factors. Journal of Psychiatric Research, 2007, 41, 435-445.	1.5	87
358	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria. Lancet Neurology, The, 2007, 6, 734-746.	4.9	3,755
359	Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease. Annals of the New York Academy of Sciences, 2007, 1097, 114-145.	1.8	177
360	Redoxâ€Reactive Autoantibodies in Cerebrospinal Fluids. Annals of the New York Academy of Sciences, 2007, 1109, 296-302.	1.8	10
361	Could linear MRI measurements of hippocampus differentiate normal brain aging in elderly persons from Alzheimer disease?. Surgical and Radiologic Anatomy, 2007, 29, 77-81.	0.6	9
362	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathologica, 2007, 114, 5-22.	3.9	978
363	Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathologica, 2007, 114, 221-229.	3.9	378
364	Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathologica, 2008, 115, 5-38.	3.9	365
365	The validity of clinical diagnoses of dementia in a group of consecutively autopsied memory clinic patients. Journal of Nutrition, Health and Aging, 2008, 12, 132-137.	1.5	15
366	Tracing of temporo-entorhinal connections in the human brain: cognitively impaired argyrophilic grain disease cases show dendritic alterations but no axonal disconnection of temporo-entorhinal association neurons. Acta Neuropathologica, 2008, 115, 175-183.	3.9	13

#	Article	IF	CITATIONS
367	Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathologica, 2008, 115, 599-609.	3.9	288
368	The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathologica, 2008, 116, 391-407.	3.9	85
369	Longitudinal followâ€up of lateâ€onset Alzheimer disease families. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 571-578.	1.1	4
370	βâ€amyloid burden is not associated with rates of brain atrophy. Annals of Neurology, 2008, 63, 204-212.	2.8	187
371	Neuropathological basis of magnetic resonance images in aging and dementia. Annals of Neurology, 2008, 63, 72-80.	2.8	282
372	Frequency and course of mild cognitive impairment in a multiethnic community. Annals of Neurology, 2008, 63, 494-506.	2.8	486
373	Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. Journal of Neuroscience Methods, 2008, 172, 277-282.	1.3	75
374	Clinicopathological Outline of Dementia with Lewy Bodies Applying the Revised Criteria: The Hisayama Study. Brain Pathology, 2008, 18, 317-325.	2.1	71
375	The Effects of Patient Function and Dependence on Costs of Care in Alzheimer's Disease. Journal of the American Geriatrics Society, 2008, 56, 1497-1503.	1.3	62
376	Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radical Biology and Medicine, 2008, 45, 813-819.	1.3	99
377	A life course of adiposity and dementia. European Journal of Pharmacology, 2008, 585, 163-175.	1.7	100
378	Oxidatively modified RNA in mild cognitive impairment. Neurobiology of Disease, 2008, 29, 169-175.	2.1	93
379	Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. Neuropsychologia, 2008, 46, 1597-1612.	0.7	116
380	Profile of memory impairment and gray matter loss in amnestic mild cognitive impairment. Neuropsychologia, 2008, 46, 1009-1019.	0.7	78
381	Age and apoE associations with complex pathologic features in Alzheimer's disease. Journal of the Neurological Sciences, 2008, 273, 34-39.	0.3	30
382	No association of SORL1 SNPs with Alzheimer's disease. Neuroscience Letters, 2008, 440, 190-192.	1.0	39
383	Translational gene mapping of cognitive decline. Neurobiology of Aging, 2008, 29, 524-541.	1.5	28
384	Detection of prodromal Alzheimer's disease via pattern classification of magnetic resonance imaging. Neurobiology of Aging, 2008, 29, 514-523.	1.5	343

#	Article	IF	CITATIONS
385	Double stranded RNA activated EIF2 α kinase (EIF2AK2; PKR) is associated with Alzheimer's disease. Neurobiology of Aging, 2008, 29, 1160-1166.	1.5	43
386	Acquisition of conditioned taste aversion is impaired in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. Neuroscience, 2008, 152, 594-600.	1.1	43
387	Rates of brain atrophy over time in autopsy-proven frontotemporal dementia and Alzheimer disease. NeuroImage, 2008, 39, 1034-1040.	2.1	52
388	Accurate prediction of V1 location from cortical folds in a surface coordinate system. NeuroImage, 2008, 39, 1585-1599.	2.1	221
389	Age effects on hippocampal structural changes in old men: The HAAS. NeuroImage, 2008, 40, 1003-1015.	2.1	37
390	Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. NeuroImage, 2008, 41, 1220-1227.	2.1	217
391	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage, 2008, 42, 559-567.	2.1	152
392	Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty years. Alzheimer's and Dementia, 2008, 4, 96-109.	0.4	333
393	Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, The, 2008, 372, 216-223.	6.3	1,333
394	Dementia of the Alzheimer Type. Epidemiologic Reviews, 2008, 30, 15-34.	1.3	126
394 395	Dementia of the Alzheimer Type. Epidemiologic Reviews, 2008, 30, 15-34. A 60-Year-Old Woman With Mild Memory Impairment. JAMA - Journal of the American Medical Association, 2008, 300, 1566.	1.3 3.8	126 15
	A 60-Year-Old Woman With Mild Memory Impairment. JAMA - Journal of the American Medical		
395	A 60-Year-Old Woman With Mild Memory Impairment. JAMA - Journal of the American Medical Association, 2008, 300, 1566. Patient Dependence and Longitudinal Changes in Costs of Care in Alzheimer's Disease. Dementia and	3.8	15
395 396	A 60-Year-Old Woman With Mild Memory Impairment. JAMA - Journal of the American Medical Association, 2008, 300, 1566. Patient Dependence and Longitudinal Changes in Costs of Care in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 416-423.	3.8 0.7	15 65
395 396 397	A 60-Year-Old Woman With Mild Memory Impairment. JAMA - Journal of the American Medical Association, 2008, 300, 1566. Patient Dependence and Longitudinal Changes in Costs of Care in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 416-423. Genetic aspects of Alzheimer disease. Genetics in Medicine, 2008, 10, 231-239. Recent Progress in the Medicinal Chemistry of γ-Secretase Inhibitors. Current Topics in Medicinal	3.8 0.7 1.1	15 65 232
395 396 397 398	A 60-Year-Old Woman With Mild Memory Impairment. JAMA - Journal of the American Medical Association, 2008, 300, 1566. Patient Dependence and Longitudinal Changes in Costs of Care in Alzheimer's Disease. Dementia and Ceriatric Cognitive Disorders, 2008, 26, 416-423. Genetic aspects of Alzheimer disease. Genetics in Medicine, 2008, 10, 231-239. Recent Progress in the Medicinal Chemistry of γ-Secretase Inhibitors. Current Topics in Medicinal Chemistry, 2008, 8, 17-33.	3.8 0.7 1.1 1.0	15 65 232 58
 395 396 397 398 399 	A 60-Year-Old Woman With Mild Memory Impairment. JAMA - Journal of the American Medical Association, 2008, 300, 1566. Patient Dependence and Longitudinal Changes in Costs of Care in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 416-423. Genetic aspects of Alzheimer disease. Genetics in Medicine, 2008, 10, 231-239. Recent Progress in the Medicinal Chemistry of γ-Secretase Inhibitors. Current Topics in Medicinal Chemistry, 2008, 8, 17-33. The Intrinsic Shape of Human and Macaque Primary Visual Cortex. Cerebral Cortex, 2008, 18, 2586-2595. Hippocampal mitochondrial dysfunction in rat aging. American Journal of Physiology - Regulatory	3.8 0.7 1.1 1.0 1.6	15 65 232 58 35

ARTICLE IF CITATIONS Nature or nurture. Neurology, 2008, 70, 1725-1727. 403 1.5 4 Automatic classification of MR scans in Alzheimer's disease. Brain, 2008, 131, 681-689. 404 3.7 1,017 Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. 405 0.9 94 Journal of Neurology, Neurosurgery and Psychiatry, 2008, 80, 366-370. Boom and Bust for Homocysteine?. Central Nervous System Agents in Medicinal Chemistry, 2008, 8, 406 0.5 107-120. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a 407 1.0 264 reference data set. Physiological Genomics, 2008, 33, 240-256. 408 Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology, 2008, 70, 25-34. 1.5 Robust and conventional neuropsychological norms: Diagnosis and prediction of age-related 409 1.0 74 cognitive decline.. Neuropsychology, 2008, 22, 469-484. Use of Magnetic Resonance Imaging to Identify Mild Cognitive Impairment: Who Should Be Imaged?. CNS 410 Spectrums, 2008, 13, 18-20. Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with 411 0.3 56 Alzheimer's disease. Éiomédical Research, 2009, 30, 227-233. Linking Hippocampal Structure and Function to Memory Performance in an Aging Population. Archives 49 of Neurology, 2009, 66, 1385-92. Twin pairs discordant for neuropathologically confirmed Lewy body dementia. Journal of Neurology, 414 0.9 20 Neurosurgery and Psychiatry, 2009, 80, 562-565. Cortical α7 Nicotinic Acetylcholine Receptor and β-Amyloid Levels in Early Alzheimer Disease. Archives of 59 Neurology, 2009, 66, 646-51. Reduction of SorLA/LR11, a Sorting Protein Limiting Î2-Amyloid Production, in Alzheimer Disease 416 4.9 79 Cerebrospinal Fluid. Archives of Neurology, 2009, 66, 448-57. Cerebrospinal Fluid Î²-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes 747 in the Brain. Archives of Neurology, 2009, 66, 382-9. Association of White Matter Hyperintensity Measurements on Brain MR Imaging with Cognitive Status, 418 Medial Temporal Atrophy, and Cardiovascular Risk Factors. American Journal of Neuroradiology, 1.2 42 2009, 30, 1870-1876. Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64–Detector Row 121 CT. Radiology, 2009, 253, 174-183. Clinical syndromes associated with posterior atrophy. Neurology, 2009, 73, 1571-1578. 420 1.5233 Carnosinase Levels in Aging Brain: Redox State Induction and Cellular Stress Response. Antioxidants 421 and Redox Signaling, 2009, 11, 2759-2775.

#	Article	IF	CITATIONS
422	Amyloid PET and MRI in Alzheimers Disease and Mild Cognitive Impairment. Current Alzheimer Research, 2009, 6, 312-319.	0.7	17
423	Memory performance is related to amyloid and tau pathology in the hippocampus. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 715-721.	0.9	30
424	Longitudinal Study of the Transition From Healthy Aging to Alzheimer Disease. Archives of Neurology, 2009, 66, 1254-9.	4.9	253
425	Biomarkers of Alzheimer's disease. Neurobiology of Disease, 2009, 35, 128-140.	2.1	175
426	Episodic simulation of future events is impaired in mild Alzheimer's disease. Neuropsychologia, 2009, 47, 2660-2671.	0.7	257
427	Identifying Anatomical Shape Difference by Regularized Discriminative Direction. IEEE Transactions on Medical Imaging, 2009, 28, 937-950.	5.4	8
428	Altered expression of claudin family proteins in Alzheimer's disease and vascular dementia brains. Journal of Cellular and Molecular Medicine, 2009, 14, no-no.	1.6	45
429	The neuropathology of probable Alzheimer disease and mild cognitive impairment. Annals of Neurology, 2009, 66, 200-208.	2.8	745
430	No association between <i>CALHM1</i> variation and risk of Alzheimer disease. Human Mutation, 2009, 30, E566-E569.	1.1	37
431	Cytomorphologic manifestations of Alzheimer's disease using brain squash smears: An autopsy study with histology–cytology correlation. Diagnostic Cytopathology, 2009, 37, 654-660.	0.5	2
432	Torpedoes in Parkinson's disease, Alzheimer's disease, essential tremor, and control brains. Movement Disorders, 2009, 24, 1600-1605.	2.2	78
433	Evidence of angiogenic vessels in Alzheimer's disease. Journal of Neural Transmission, 2009, 116, 587-597.	1.4	126
434	A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathologica, 2009, 118, 505-517.	3.9	41
435	Classification and basic pathology of Alzheimer disease. Acta Neuropathologica, 2009, 118, 5-36.	3.9	805
436	TARDBP 3′-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathologica, 2009, 118, 633-645.	3.9	139
437	FDC-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 811-822.	3.3	409
438	Expression of SORL1 and a novel SORL1 splice variant in normal and Alzheimers disease brain. Molecular Neurodegeneration, 2009, 4, 46.	4.4	53
439	The dorsal raphe nucleus shows phosphoâ€ŧau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset?. Neuropathology and Applied Neurobiology, 2009, 35, 406-416.	1.8	186

#	Article	IF	CITATIONS
440	Does Alzheimer's disease begin in the brainstem?. Neuropathology and Applied Neurobiology, 2009, 35, 532-554.	1.8	170
441	Imaging Biomarkers in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 20-27.	1.8	9
442	Detergentâ€Insoluble EAAC1/EAAT3 Aberrantly Accumulates in Hippocampal Neurons of Alzheimer's Disease Patients. Brain Pathology, 2009, 19, 267-278.	2.1	45
443	Frontotemporal lobar degeneration and dementia with Lewy bodies: Clinicopathological issues associated with antemortem diagnosis. Psychogeriatrics, 2009, 9, 91-102.	0.6	3
444	A free radicalâ€generating system induces the cholesterol biosynthesis pathway: a role in Alzheimer's disease. Aging Cell, 2009, 8, 128-139.	3.0	36
445	Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 133-139.	0.9	72
447	Proteomics Analysis Reveals Novel Components in the Detergent-Insoluble Subproteome in Alzheimer's Disease. Journal of Proteome Research, 2009, 8, 5069-5079.	1.8	76
448	Neuropathology of Lewy body disorders. Brain Research Bulletin, 2009, 80, 203-210.	1.4	59
449	Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiology of Aging, 2009, 30, 1936-1948.	1.5	116
450	Alzheimer disease neuropathology in the oldest old. Nature Reviews Neurology, 2009, 5, 411-412.	4.9	9
451	Age-associated oxidative damage to the p62 promoter: implications for Alzheimer disease. Free Radical Biology and Medicine, 2009, 46, 492-501.	1.3	96
452	Early risk assessment for Alzheimer's disease. Alzheimer's and Dementia, 2009, 5, 182-196.	0.4	34
453	Signal Regulatory Protein- \hat{l}^21 . American Journal of Pathology, 2009, 175, 2528-2539.	1.9	66
454	Changing perspectives regarding late-life dementia. Nature Reviews Neurology, 2009, 5, 649-658.	4.9	259
455	MRI in Dementia. Neurologic Clinics, 2009, 27, 221-236.	0.8	7
456	Adiposity and Alzheimer's disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2009, 12, 15-21.	1.3	130
457	Changes in Relative Glucose Metabolic Rate Following Cortisol Administration in Aging Veterans with Posttraumatic Stress Disorder: An FDG-PET Neuroimaging Study. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 132-143.	0.9	34
458	Alzheimer's Disease and Other Dementias (Including Pseudodementias). , 0, , 543-615.		35

#	Article	IF	CITATIONS
459	Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer's disease. International Psychogeriatrics, 2009, 21, 688-695.	0.6	16
460	11 The Early Detection of Alzheimer's Disease with Positron Emission Tomography. , 2009, , 151-168.		0
461	Hippocampal Asymmetry with Hippocampal Sulcus Remnants in a Patient with Mild Cognitive Impairment. Neuroradiology Journal, 2010, 23, 393-397.	0.6	1
462	Putative CSF protein biomarker candidates for amnestic mild cognitive impairment. Translational Neuroscience, 2010, 1, 2-8.	0.7	12
463	Alzheimer Disease. Disease-a-Month, 2010, 56, 484-546.	0.4	391
464	Are there differences in cerebral white matter lesion burdens between Parkinson's disease patients with or without dementia?. Acta Neuropathologica, 2010, 119, 147-149.	3.9	40
465	Vascular pathology in the aged human brain. Acta Neuropathologica, 2010, 119, 277-290.	3.9	275
466	Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathologica, 2010, 119, 421-433.	3.9	215
467	Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathologica, 2010, 119, 523-541.	3.9	341
468	TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathologica, 2010, 120, 43-54.	3.9	70
469	Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathologica, 2010, 120, 55-66.	3.9	97
470	Capillary cerebral amyloid angiopathy identifies a distinct APOE ε4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathologica, 2010, 120, 169-183.	3.9	81
471	Brain biopsy in dementia: clinical indications and diagnostic approach. Acta Neuropathologica, 2010, 120, 327-341.	3.9	64
472	Effect of topographical distribution of α-synuclein pathology on TDP-43 accumulation in Lewy body disease. Acta Neuropathologica, 2010, 120, 789-801.	3.9	31
473	Taste in mild cognitive impairment and Alzheimer's disease. Journal of Neurology, 2010, 257, 238-246.	1.8	96
474	Low sensitivity in clinical diagnoses of dementia with Lewy bodies. Journal of Neurology, 2010, 257, 359-366.	1.8	233
475	Age-Related Changes of Elements and Relationships Among Elements in Human Hippocampus, Dentate Gyrus, and Fornix. Biological Trace Element Research, 2010, 138, 42-52.	1.9	12
477	Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. BMC Neuroscience, 2010, 11, 23.	0.8	25

#	Article	IF	CITATIONS
478	3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Human Brain Mapping, 2010, 31, 786-797.	1.9	91
479	Anatomical differences between CBSâ€corticobasal degeneration and CBSâ€Alzheimer's disease. Movement Disorders, 2010, 25, 1246-1252.	2.2	71
480	A novel Xâ€linked fourâ€repeat tauopathy with Parkinsonism and spasticity. Movement Disorders, 2010, 25, 1409-1417.	2.2	20
481	Spatially pathogenic forms of tau detected in Alzheimer's disease brain tissue by fluorescence lifetime-based FA¶rster resonance energy transfer. Journal of Neuroscience Methods, 2010, 192, 127-137.	1.3	2
482	Interpretation of neuropathological lesions: Its limitations in medico-legal experts' reports. Forensic Science International, 2010, 194, e1-e3.	1.3	0
483	Quantitative and Qualitative Measures of Hippocampal Atrophy Are Not Correlated in Healthy Older Men. Journal of Neuroimaging, 2010, 20, 157-162.	1.0	10
484	Burden of Neurodegenerative Diseases in a Cohort of Medical Examiner Subjects*. Journal of Forensic Sciences, 2010, 55, 642-645.	0.9	8
485	Brain pathology in three subjects from the same pedigree with presenilin-1 (<i>PSEN1</i>) P264L mutation. Neuropathology and Applied Neurobiology, 2010, 36, 41-54.	1.8	22
486	Association Between Lifetime Cigarette Smoking and Lewy Body Accumulation. Brain Pathology, 2010, 20, 412-418.	2.1	29
487	Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry. Journal of Lipid Research, 2010, 51, 598-605.	2.0	95
489	Prediction of pathology in primary progressive language and speech disorders. Neurology, 2010, 74, 42-49.	1.5	187
490	Inability of Plasma and Urine F2A-Isoprostane Levels to Differentiate Mild Cognitive Impairment from Alzheimer's Disease. Neurodegenerative Diseases, 2010, 7, 139-142.	0.8	32
491	MRI in Dementia. Magnetic Resonance Imaging Clinics of North America, 2010, 18, 121-132.	0.6	2
492	Multiple brain pathologies in dementia are common. European Geriatric Medicine, 2010, 1, 259-265.	1.2	20
493	Toward a pathological definition of vascular dementia. Journal of the Neurological Sciences, 2010, 299, 136-138.	0.3	64
494	Phosphoproteomic Analysis Reveals Site-Specific Changes in GFAP and NDRG2 Phosphorylation in Frontotemporal Lobar Degeneration. Journal of Proteome Research, 2010, 9, 6368-6379.	1.8	71
495	Genetic Factors in Alzheimer Disease and Dementia. , 2010, , 681-697.		0
496	Preservation of cortical sortilin protein levels in MCI and Alzheimer's disease. Neuroscience Letters, 2010, 471, 129-133.	1.0	40

#	Article	IF	CITATIONS
497	Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neuroscience Letters, 2010, 486, 19-23.	1.0	60
498	Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease. Journal of Chemical Neuroanatomy, 2010, 40, 63-70.	1.0	31
499	Evidence of neurodegeneration in brains of older adults who do not yet fulfill MCI criteria. Neurobiology of Aging, 2010, 31, 368-377.	1.5	46
500	Rate of entorhinal and hippocampal atrophy in incipient and mild AD: Relation to memory function. Neurobiology of Aging, 2010, 31, 1089-1098.	1.5	93
501	Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiology of Aging, 2010, 31, 1805-1813.	1.5	93
502	Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors. Experimental Neurology, 2010, 223, 304-310.	2.0	81
503	Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: The essential role of the Neuropathology Core. Alzheimer's and Dementia, 2010, 6, 274-279.	0.4	31
504	Imaging correlates of pathology in corticobasal syndrome. Neurology, 2010, 75, 1879-1887.	1.5	203
505	Review Article: Genetics of Alzheimer Disease. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 213-227.	1.2	748
506	Immunohistology of the Nervous System. , 2010, , 820-889.		8
506 507	Immunohistology of the Nervous System. , 2010, , 820-889. Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 20.	3.0	8
	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal	3.0 3.0	
507	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 20. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review.		78
507 508	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 20. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimer's Research and Therapy, 2011, 3, 36. Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND.	3.0	78 130
507 508 510	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 20. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimer's Research and Therapy, 2011, 3, 36. Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. NeuroImage, 2011, 55, 522-531. The relationship between cortical sulcal variability and cognitive performance in the elderly.	3.0 2.1	78 130 90
507 508 510 511	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 20. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimer's Research and Therapy, 2011, 3, 36. Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. NeuroImage, 2011, 55, 522-531. The relationship between cortical sulcal variability and cognitive performance in the elderly. NeuroImage, 2011, 56, 865-873. Synaptic Loss in the Inferior Temporal Gyrus in Mild Cognitive Impairment and Alzheimer's Disease.	3.0 2.1 2.1	78 130 90 45
507 508 510 511 512	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 20. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimer's Research and Therapy, 2011, 3, 36. Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. NeuroImage, 2011, 55, 522-531. The relationship between cortical sulcal variability and cognitive performance in the elderly. NeuroImage, 2011, 56, 865-873. Synaptic Loss in the Inferior Temporal Cyrus in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 547-557. Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With	3.0 2.1 2.1 1.2	 78 130 90 45 231

		CITATION REPORT		
#	ARTICLE		IF	CITATIONS
516	Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiology of Aging, 2011, 32	, 257-271.	1.5	49
517	Cathepsin D gene and the risk of Alzheimer's disease: A population-based study and meta-ana Neurobiology of Aging, 2011, 32, 1607-1614.	alysis.	1.5	43
518	Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. Neurol of Aging, 2011, 32, 1531-1541.	piology	1.5	105
519	Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the America College of Medical Genetics and the National Society of Genetic Counselors. Genetics in Med 2011, 13, 597-605.	n icine,	1.1	297
520	Revision of the criteria for Alzheimer's disease: A symposium. Alzheimer's and Dementia, 201	1, 7, e1-12.	0.4	33
521	Frequency of Alzheimer's disease pathology at autopsy in patients with clinical normal pressund hydrocephalus. Alzheimer's and Dementia, 2011, 7, 509-513.	ire	0.4	121
522	Biomarkers Predicting Alzheimer's Disease in Cognitively Normal Aging. Journal of Clinical New	urology		

#	Article	IF	CITATIONS
534	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. Acta Neuropathologica, 2011, 122, 737-745.	3.9	15
535	Reduced clinical and postmortem measures of cardiac pathology in subjects with advanced Alzheimer's Disease. BMC Geriatrics, 2011, 11, 3.	1.1	18
536	Hippocampal blood flow in normal aging measured with arterial spin labeling at 3T. Magnetic Resonance in Medicine, 2011, 65, 128-137.	1.9	26
537	<i>CR1</i> is associated with amyloid plaque burden and ageâ€related cognitive decline. Annals of Neurology, 2011, 69, 560-569.	2.8	148
538	Clinicopathological correlations in corticobasal degeneration. Annals of Neurology, 2011, 70, 327-340.	2.8	367
539	White matter lesions defined by diffusion tensor imaging in older adults. Annals of Neurology, 2011, 70, 465-476.	2.8	104
540	Astrocytic Redox Remodeling by Amyloid Beta Peptide. Antioxidants and Redox Signaling, 2011, 14, 2385-2397.	2.5	13
541	Dementia Risk in Parkinson Disease. Archives of Neurology, 2011, 68, 359-64.	4.9	125
542	Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain, 2011, 134, 1493-1505.	3.7	497
543	Use of Florbetapir-PET for Imaging β-Amyloid Pathology. JAMA - Journal of the American Medical Association, 2011, 305, 275.	3.8	927
544	Longitudinal Changes in Cognition in Parkinson's Disease with and without Dementia. Dementia and Geriatric Cognitive Disorders, 2011, 31, 98-108.	0.7	35
545	Hippocampal Atrophy Relates to Fluid Intelligence Decline in the Elderly. Journal of the International Neuropsychological Society, 2011, 17, 56-61.	1.2	37
546	A novel origin for granulovacuolar degeneration in aging and Alzheimer's disease: parallels to stress granules. Laboratory Investigation, 2011, 91, 1777-1786.	1.7	44
547	High doses of vitamin E improve mitochondrial dysfunction in rat hippocampus and frontal cortex upon aging. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 300, R827-R834.	0.9	39
548	Comparison of Verbal Episodic Memory Measures: Consortium to Establish a Registry for Alzheimer's DiseaseNeuropsychological Assessment Battery (CERAD-NAB) versus California Verbal Learning Test (CVLT). Archives of Clinical Neuropsychology, 2012, 27, 510-519.	0.3	33
549	Molecular Brain Imaging in the Multimodality Era. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1377-1392.	2.4	16
550	A Population-Based Clinicopathological Study in the Oldest-Old: The 90+ Study. Current Alzheimer Research, 2012, 9, 709-717.	0.7	118
551	Overview and Findings from the Religious Orders Study. Current Alzheimer Research, 2012, 9, 628-645.	0.7	582

#	Article	IF	CITATIONS
552	Correlation of Amyloid PET Ligand Florbetapir F 18 Binding With AÎ ² Aggregation and Neuritic Plaque Deposition in Postmortem Brain Tissue. Alzheimer Disease and Associated Disorders, 2012, 26, 8-16.	0.6	112
553	Learning and Generalization in Healthy Aging. Cognitive and Behavioral Neurology, 2012, 25, 7-15.	0.5	9
554	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. Advances in Pharmacology, 2012, 64, 27-81.	1.2	78
555	Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline. Neurology, 2012, 79, 1636-1644.	1.5	206
556	Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults. Neurology, 2012, 78, 1769-1776.	1.5	46
557	Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging in Medicine, 2012, 4, 343-357.	0.0	12
558	Hippocampal Drebrin Loss in Mild Cognitive Impairment. Neurodegenerative Diseases, 2012, 10, 216-219.	0.8	75
559	Neuropathological Basis of AlzheimerÂ's Disease and AlzheimerÂ's Disease Diagnosis. Advances in Biological Psychiatry, 2012, , 49-70.	0.2	1
560	<scp>EFNS</scp> task force: the use of neuroimaging in the diagnosis of dementia. European Journal of Neurology, 2012, 19, 1487-1501.	1.7	112
561	Srp20 regulates TrkB preâ€mRNA splicing to generate TrkBâ€5hc transcripts with implications for Alzheimer's disease. Journal of Neurochemistry, 2012, 123, 159-171.	2.1	28
562	Quantitative Analysis of the Detergent-Insoluble Brain Proteome in Frontotemporal Lobar Degeneration Using SILAC Internal Standards. Journal of Proteome Research, 2012, 11, 2721-2738.	1.8	61
563	Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurology, The, 2012, 11, 669-678.	4.9	674
564	Pittsburgh compound B and the postmortem diagnosis of alzheimer disease. Annals of Neurology, 2012, 72, 564-570.	2.8	31
565	Neuropathologic substrates of Parkinson disease dementia. Annals of Neurology, 2012, 72, 587-598.	2.8	401
566	Localization of fused in sarcoma (FUS) protein to the post-synaptic density in the brain. Acta Neuropathologica, 2012, 124, 383-394.	3.9	40
567	Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimer's and Dementia, 2012, 8, 496-501.	0.4	116
568	Brain on stress: How the social environment gets under the skin. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17180-17185.	3.3	891
569	Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiology of Aging, 2012, 33, 856-866.	1.5	55

#	Article	IF	CITATIONS
570	Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. Neurobiology of Aging, 2012, 33, 1034-1044.	1.5	76
571	Amyloid beta selectively modulates neuronal TrkB alternative transcript expression with implications for Alzheimer's disease. Neuroscience, 2012, 210, 363-374.	1.1	33
572	Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathologica, 2012, 124, 643-664.	3.9	130
573	Bid signal pathway components are identified in the temporal cortex with Parkinson disease. Neurology, 2012, 79, 1767-1773.	1.5	15
574	The ageing cortical synapse: hallmarks and implications for cognitive decline. Nature Reviews Neuroscience, 2012, 13, 240-250.	4.9	810
575	Should Alzheimer's disease be equated with human brain ageing?: A maladaptive interaction between brain evolution and senescence. Ageing Research Reviews, 2012, 11, 104-122.	5.0	18
576	Response of ERÎ ² and aromatase expression in the monkey hippocampal formation to ovariectomy and menopause. Neuroscience Research, 2012, 72, 148-154.	1.0	19
577	Right temporal variant frontotemporal dementia with motor neuron disease. Journal of Clinical Neuroscience, 2012, 19, 85-91.	0.8	20
578	Mitochondria and Cell Bioenergetics: Increasingly Recognized Components and a Possible Etiologic Cause of Alzheimer's Disease. Antioxidants and Redox Signaling, 2012, 16, 1434-1455.	2.5	169
579	Smallâ€vessel disease in patients with Parkinson's disease: A clinicopathological study. Movement Disorders, 2012, 27, 1506-1512.	2.2	49
580	Asparaginyl endopeptidase cleaves TDPâ€43 in brain. Proteomics, 2012, 12, 2455-2463.	1.3	52
581	Alzheimer's Disease and the Amyloid β-Protein. Progress in Molecular Biology and Translational Science, 2012, 107, 101-124.	0.9	106
582	Multiple Findings in Elderly Adults with Confirmed <scp>A</scp> lzheimer's Disease. Journal of the American Geriatrics Society, 2012, 60, 2169-2170.	1.3	0
583	Measures to Support Voluntary Retirement From Driving in <scp>J</scp> apanese Older People: Driving Is Not Just a Means of Transportation. Journal of the American Geriatrics Society, 2012, 60, 2170-2172.	1.3	1
584	Decreased Oligodendrocyte Nuclear Diameter in Alzheimer's Disease and Lewy Body Dementia. Brain Pathology, 2012, 22, 803-810.	2.1	28
585	Increased Risk of Breast Cancer Associated with CC Genotype of Has-miR-146a Rs2910164 Polymorphism in Europeans. PLoS ONE, 2012, 7, e31615.	1.1	67
586	Na+ and K+ ion imbalances in Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1671-1681.	1.8	105
587	Structural and diffusion MRI measures of the hippocampus and memory performance. NeuroImage, 2012, 63, 1782-1789.	2.1	88

#	Article	IF	CITATIONS
588	Hippocampal atrophy in Alzheimer's disease. Neurodegenerative Disease Management, 2012, 2, 197-209.	1.2	2
589	Overview of Mouse Models for Psychiatric and Neurologic Disorders. , 2012, , 738-751.		0
590	Genetics of Clusterin Isoform Expression and Alzheimer's Disease Risk. PLoS ONE, 2012, 7, e33923.	1.1	60
591	Neuronal LR11 Expression Does Not Differentiate between Clinically-Defined Alzheimer's Disease and Control Brains. PLoS ONE, 2012, 7, e40527.	1.1	10
592	Behavioral and psychological symptoms and hippocampal atrophy in subcortical ischaemic vascular disease. Dementia E Neuropsychologia, 2012, 6, 175-179.	0.3	3
593	Staging and natural history of cerebrovascular pathology in dementia. Neurology, 2012, 78, 1043-1050.	1.5	245
594	TOMM40 in Cerebral Amyloid Angiopathy Related Intracerebral Hemorrhage: Comparative Genetic Analysis with Alzheimer's Disease. Translational Stroke Research, 2012, 3, 102-112.	2.3	23
595	Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes, Brain and Behavior, 2012, 11, 577-585.	1.1	117
596	Divergent clinical and neuropathological phenotype in a Gerstmann-Strässler-Scheinker P102L family. Acta Neurologica Scandinavica, 2012, 126, 315-323.	1.0	13
597	Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	3.3	55
598	Neuropathologic analysis of Lewyâ€related αâ€synucleinopathy in olfactory mucosa. Neuropathology, 2013, 33, 47-58.	0.7	42
599	A Phenotypic Change But Not Proliferation Underlies Glial Responses in Alzheimer Disease. American Journal of Pathology, 2013, 182, 2332-2344.	1.9	131
600	Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease. JAMA Neurology, 2013, 70, 1158.	4.5	566
601	The <i>APOE</i> Îμ4/Îμ4 Genotype Potentiates Vascular Fibrin(Ogen) Deposition in Amyloid-Laden Vessels in the Brains of Alzheimer's Disease Patients. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1251-1258.	2.4	131
602	Genetic Susceptibility for Alzheimer Disease Neuritic Plaque Pathology. JAMA Neurology, 2013, 70, 1150.	4.5	143
603	Body mass index, lifestyles, physical performance and cognitive decline: The "Treviso Longeva (Trelong)―study. Journal of Nutrition, Health and Aging, 2013, 17, 378-384.	1.5	57
604	Neurotoxic Saboteurs: Straws that Break the Hippo's (Hippocampus) Back Drive Cognitive Impairment and Alzheimer's Disease. Neurotoxicity Research, 2013, 24, 407-459.	1.3	47
605	The influence of Apolipoprotein E genotype on regional pathology in Alzheimer's disease. BMC Neurology, 2013, 13, 44.	0.8	23

#	Article	IF	CITATIONS
606	3â€hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Movement Disorders, 2013, 28, 1653-1660.	2.2	127
607	Genetics of Alzheimer Disease. , 2013, , 1-20.		0
608	The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathologica Communications, 2013, 1, 31.	2.4	148
609	ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathologica Communications, 2013, 1, 11.	2.4	61
610	Resting metabolic connectivity in Alzheimer's disease. Clinical and Translational Imaging, 2013, 1, 271-278.	1.1	9
611	The common dementias: a pictorial review. European Radiology, 2013, 23, 3405-3417.	2.3	28
612	Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain, 2013, 136, 2697-2706.	3.7	609
613	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathologica Communications, 2013, 1, 65.	2.4	138
614	Antimicrobial peptide β-defensin-1 expression is upregulated in Alzheimer's brain. Journal of Neuroinflammation, 2013, 10, 127.	3.1	41
615	Age-related appearance of dendritic inclusions in catecholaminergic brainstem neurons. Neurobiology of Aging, 2013, 34, 286-297.	1.5	19
616	Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. Neurobiology of Aging, 2013, 34, 1653-1661.	1.5	261
617	Early neuropsychological discriminants for Lewy body disease: an autopsy series. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1326-1330.	0.9	53
618	Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer's disease. Acta Neuropathologica, 2013, 125, 187-199.	3.9	67
619	Age-dependent alterations in the number, volume, and localization of islands ofÂCalleja within the olfactory tubercle. Neurobiology of Aging, 2013, 34, 2676-2682.	1.5	12
620	Calcyclin binding protein and Siah-1 interacting protein in Alzheimer's disease pathology: neuronal localization and possible function. Neurobiology of Aging, 2013, 34, 1380-1388.	1.5	32
621	A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer' disease. Hormones and Behavior, 2013, 64, 1-7.	1.0	92
622	Neuropathologic Basis of Age-Associated Brain Atrophy. JAMA Neurology, 2013, 70, 616.	4.5	90
623	Screening for predementia AD. Neurology, 2013, 80, 1307-1314.	1.5	96

#	Article	IF	CITATIONS
624	Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer's brains. Acta Neuropathologica, 2013, 125, 861-878.	3.9	107
625	Functional microRNAs in Alzheimer's disease and cancer: differential regulation of common mechanisms and pathway. Frontiers in Genetics, 2012, 3, 323.	1.1	63
626	Dementia in the oldest old. Nature Reviews Neurology, 2013, 9, 382-393.	4.9	58
627	Type 2 Diabetes as a Risk Factor for Alzheimer's Disease: The Confounders, Interactions, and Neuropathology Associated With This Relationship. Epidemiologic Reviews, 2013, 35, 152-160.	1.3	252
628	Specific changes of sulfatide levels in individuals with preâ€clinical Alzheimer's disease: an early event in disease pathogenesis. Journal of Neurochemistry, 2013, 127, 733-738.	2.1	84
629	Assessing White Matter Ischemic Damage in Dementia Patients by Measurement of Myelin Proteins. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1050-1057.	2.4	64
630	MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers, 2013, 18, 455-466.	0.9	102
631	Quantitative measurement of MR cortical atrophy: MR brain surface intensity model (BSIM) and group and individual cortical thinning studies. , 2013, , .		1
632	Semantic Memory Functional MRI and Cognitive Function after Exercise Intervention in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2013, 37, 197-215.	1.2	121
633	Patterns of Striatal Degeneration in Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2013, 27, 74-83.	0.6	55
634	Examination of the Clinicopathologic Continuum of Alzheimer Disease in the Autopsy Cohort of the National Alzheimer Coordinating Center. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1182-1192.	0.9	89
635	Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline. Alzheimer Disease and Associated Disorders, 2013, 27, 4-15.	0.6	109
636	Prions and Diseases. , 2013, , .		0
637	Cerebrospinal fluid biomarkers of AlzheimerÂ's disease in cognitively healthy elderly. Frontiers in Bioscience - Landmark, 2013, 18, 1150.	3.0	16
638	A Mechanistic Approach to Individual Differences in Spatial Learning, Memory, and Navigation. Psychology of Learning and Motivation - Advances in Research and Theory, 2013, 59, 223-259.	0.5	17
639	MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging. Frontiers in Aging Neuroscience, 2014, 6, 23.	1.7	16
640	Therapeutic and diagnostic challenges for frontotemporal dementia. Frontiers in Aging Neuroscience, 2014, 6, 204.	1.7	17
641	Obesity and cognitive decline: role of inflammation and vascular changes. Frontiers in Neuroscience, 2014, 8, 375.	1.4	290

ARTICLE IF CITATIONS # ABCA5 Regulates Amyloid-Î² Peptide Production and is Associated with Alzheimer's Disease 642 1.2 40 Neuropathology. Journal of Alzheimer's Disease, 2014, 43, 857-869. 643 Biomarkers of Alzheimer's disease. , 2014, , 801-815. The alternative splicing of the apolipoprotein E gene is unperturbed in the brains of Alzheimer's 644 1.0 13 disease patients. Molecular Biology Reports, 2014, 41, 6365-6376. Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study. 645 168 Molecular Psychiatry, 2014, 19, 1044-1051. Overexpression of Heme Oxygenase 1 Causes Cognitive Decline and Affects Pathways for Tauopathy in 646 1.2 34 Mice. Journal of Alzheimer's Disease, 2014, 43, 519-534. In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology. 1.5 Neurology, 2014, 82, 239-247. 648 Radiation dosimetry of florbetapir F 18. EJNMMI Research, 2014, 4, 4. 1.1 16 649 Practical utility of amyloid and FDG-PET in an academic dementia center. Neurology, 2014, 82, 230-238. 1.5 650 Prevalence of mixed pathologies in the aging brain. Alzheimer's Research and Therapy, 2014, 6, 82. 3.0 232 Theoretical Impact of Florbetapir (¹⁸F) Amyloid Imaging on Diagnosis of Alzheimer Dementia and Detection of Preclinical Cortical Amyloid. Journal of Neuropathology and Experimental Neurology, 2014, 73, 948-953. Clinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers. 652 0.9 65 Journal of Neuropathology and Experimental Neurology, 2014, 73, 244-252. Neuropathologic Changes of Multiple System Atrophy and Diffuse Lewy Body Disease. Seminars in 0.5 Neurology, 2014, 34, 210-216. Alzheimer's diseaseâ€related plagues in nondemented subjects. Alzheimer's and Dementia, 2014, 10, 654 0.4 8 522-529. Pituitary adenylate cyclase-activating polypeptide protects against \hat{l}^2 -amyloid toxicity. Neurobiology of Aging, 2014, 35, 2064-2071. 1.5 Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) 656 2.1 56 radioligand, [18F]-FEPPA. NeuroImage, 2014, 84, 868-875. Concomitant pathologies among a spectrum of parkinsonian disorders. Parkinsonism and Related Disorders, 2014, 20, 525-529. Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Annals of 658 2.8 90 Neurology, 2014, 75, 597-601. A quantitative study of α-synuclein pathology in fifteen cases of dementia associated with Parkinson 659 1.4 disease. Journal of Neural Transmission, 2014, 121, 171-181.

		Report	
#	Article	IF	CITATIONS
660	Staging TDP-43 pathology in Alzheimer's disease. Acta Neuropathologica, 2014, 127, 441-450.	3.9	278
661	New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 865-870.	0.9	195
662	Sleep is related to neuron numbers in the ventrolateral preoptic/intermediate nucleus in older adults with and without Alzheimer's disease. Brain, 2014, 137, 2847-2861.	3.7	136
663	Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity. Acta Neuropathologica Communications, 2014, 2, 83.	2.4	39
664	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathologica, 2014, 127, 811-824.	3.9	336
665	TDP-43 in Alzheimer's disease is not associated with clinical FTLD or Parkinsonism. Journal of Neurology, 2014, 261, 1344-1348.	1.8	22
666	Gray-matter macrostructure in cognitively healthy older persons: associations with age and cognition. Brain Structure and Function, 2014, 219, 2029-2049.	1.2	37
667	Parallels Between Major Depressive Disorder and Alzheimer's Disease: Role of Oxidative Stress and Genetic Vulnerability. Cellular and Molecular Neurobiology, 2014, 34, 925-949.	1.7	82
668	Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non–Alzheimer's disease tauopathies. Alzheimer's Research and Therapy, 2014, 6, 11.	3.0	68
669	Neurodegenerative disease diagnosis using incomplete multi-modality data via matrix shrinkage and completion. NeuroImage, 2014, 91, 386-400.	2.1	87
670	Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's disease model. Nature Communications, 2014, 5, 4159.	5.8	215
671	Milk and Dairy Consumption and Risk of Dementia in an Elderly <scp>J</scp> apanese Population: The <scp>H</scp> isayama Study. Journal of the American Geriatrics Society, 2014, 62, 1224-1230.	1.3	92
672	Alzheimer's-related changes in non-demented essential tremor patients vs. controls: Links between tau and tremor?. Parkinsonism and Related Disorders, 2014, 20, 655-658.	1.1	31
673	Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1527-1538.	1.8	38
674	Cognitive and Neuroimaging Profiles in Mild Cognitive Impairment and Alzheimer's Disease: Data from the Spanish Multicenter Normative Studies (NEURONORMA Project). Journal of Alzheimer's Disease, 2014, 41, 887-901.	1.2	28
675	Anosognosia and Anosodiaphoria in Mild Cognitive Impairment and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2014, 4, 465-480.	0.6	13
676	BFLCRM: A Bayesian functional linear Cox regression model for predicting time to conversion to Alzheimer's disease. Annals of Applied Statistics, 2015, 9, 2153-2178.	0.5	24
677	Impaired Parahippocampus Connectivity inÂMild Cognitive Impairment andÂAlzheimer's Disease. Journal of Alzheimer's Disease, 2016, 49, 1051-1064.	1.2	50

#	Article	IF	CITATIONS
678	Practical cutâ€offs for visual rating scales of medial temporal, frontal and posterior atrophy in <scp>A</scp> lzheimer's disease and mild cognitive impairment. Journal of Internal Medicine, 2015, 278, 277-290.	2.7	91
679	Metabolic Alterations Associated to Brain Dysfunction in Diabetes. , 2015, 6, 304-21.		70
680	Dendritic atrophy constricts functional maps in resonance and impedance properties of hippocampal model neurons. Frontiers in Cellular Neuroscience, 2014, 8, 456.	1.8	26
681	Comparative quantitative study of â€~signature' pathological lesions in the hippocampus and adjacent gyri of 12 neurodegenerative disorders. Journal of Neural Transmission, 2015, 122, 1355-1367.	1.4	14
682	Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease. Annals of Nuclear Medicine, 2015, 29, 570-581.	1.2	10
683	The brain on stress: Insight from studies using the Visible Burrow System. Physiology and Behavior, 2015, 146, 47-56.	1.0	28
684	Relationship between hippocampal atrophy and neuropathology markers: A 7T MRI validation study of the EADCâ€ADNI HarmonizedÂHippocampal Segmentation Protocol. Alzheimer's and Dementia, 2015, 11, 139-150.	0.4	61
685	Hippocampal Atrophy Varies by Neuropsychologically Defined MCI Among Men in Their 50s. American Journal of Geriatric Psychiatry, 2015, 23, 456-465.	0.6	20
686	Amyloid βâ€ e brogated TrkA ubiquitination in <scp>PC</scp> 12 cells analogous to Alzheimer's disease. Journal of Neurochemistry, 2015, 133, 919-925.	2.1	31
687	Inflammation as a mediator of the relationship between cortical thickness and metabolic syndrome. Brain Imaging and Behavior, 2015, 9, 737-743.	1.1	16
688	Insights into cognitive aging and Alzheimer's disease using amyloid PET and structural MRI scans. Clinical and Translational Imaging, 2015, 3, 65-74.	1.1	7
689	Selective activation of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25–35-mediated cognitive deficits in mice. Neuroscience, 2015, 298, 81-93.	1.1	62
690	Kaolin-induced chronic hydrocephalus accelerates amyloid deposition and vascular disease in transgenic rats expressing high levels of human APP. Fluids and Barriers of the CNS, 2015, 12, 2.	2.4	23
691	Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimer's Research and Therapy, 2015, 7, 8.	3.0	32
692	Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1225-1233.	0.9	114
693	The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study. Journal of Neural Transmission, 2015, 122, 975-991.	1.4	8
694	Cerebrospinal Fluid Biomarkers Distinguish Postmortem-Confirmed Alzheimer's Disease from Other Dementias and Healthy Controls in the OPTIMA Cohort. Journal of Alzheimer's Disease, 2015, 44, 525-539.	1.2	69
695	Recognizing resilience: Learning from the effects of stress on the brain. Neurobiology of Stress, 2015, 1, 1-11.	1.9	260

# 696	ARTICLE The neurobiology of speech perception decline in aging. Brain Structure and Function, 2015, 220, 979-997.	IF 1.2	Citations 37
697	Aggregate effects of vascular risk factors on cerebrovascular changes in autopsyâ€confirmed Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 394.	0.4	85
698	Structural Imaging of Dementia. , 2016, , .		0
699	Recent Increases in Hippocampal Tau Pathology in the Aging Japanese Population: The Hisayama Study. Journal of Alzheimer's Disease, 2016, 55, 613-624.	1.2	12
700	Progressive Bidirectional Age-Related Changes in Default Mode Network Effective Connectivity across Six Decades. Frontiers in Aging Neuroscience, 2016, 8, 137.	1.7	6
701	Amyloid Plaques in Retina for Diagnosis in Alzheimer's Patients: a Meta-Analysis. Frontiers in Aging Neuroscience, 2016, 8, 267.	1.7	28
702	Structural MR Imaging in the Diagnosis of Alzheimer's Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives. Korean Journal of Radiology, 2016, 17, 827.	1.5	61
703	Central Role of the Brain in Stress and Adaptation. , 2016, , 39-55.		10
704	Interaction Between Midlife Blood Glucose and APOE Genotype Predicts Later Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2016, 53, 1553-1562.	1.2	23
705	Alterations of the volatile metabolome in mouse models of Alzheimer's disease. Scientific Reports, 2016, 6, 19495.	1.6	29
706	Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. Journal of Parkinson's Disease, 2016, 6, 153-163.	1.5	58
707	Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not aÂHomogeneous Clinical Entity. Journal of Alzheimer's Disease, 2016, 55, 1019-1029.	1.2	24
708	Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behavioural Brain Research, 2016, 311, 54-69.	1.2	99
709	Aging is associated with dimerization and inactivation of the brain-enriched tyrosine phosphatase STEP. Neurobiology of Aging, 2016, 41, 25-38.	1.5	17
710	The long-term association between physical activity and risk of dementia in the community: the Hisayama Study. European Journal of Epidemiology, 2016, 31, 267-274.	2.5	67
711	Mammillary Bodies in Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 247-256.	0.9	19
712	Structural brain aging and speech production: a surface-based brain morphometry study. Brain Structure and Function, 2016, 221, 3275-3299.	1.2	21
713	Multiregional Age-Associated Reduction of Brain Neuronal Reserve Without Association With Neurofibrillary Degeneration or β-Amyloidosis. Journal of Neuropathology and Experimental Neurology, 2017, 76, 439-457.	0.9	14

#	Article	IF	CITATIONS
714	Targeting Adult Neurogenesis to Optimize Hippocampal Circuits in Aging. Neurotherapeutics, 2017, 14, 630-645.	2.1	39
715	Four Decades of Research in Alzheimer's Disease (1975–2014): A Bibliometric and Scientometric Analysis. Journal of Alzheimer's Disease, 2017, 59, 763-783.	1.2	33
716	A six-month longitudinal evaluation significantly improves accuracy of predicting incipient Alzheimer's disease in mild cognitive impairment. Journal of Neuroradiology, 2017, 44, 381-387.	0.6	23
717	Decreased Expression of Sulfatase 2 in the Brains of Alzheimer's Disease Patients: Implications for Regulation of Neuronal Cell Signaling. Journal of Alzheimer's Disease Reports, 2017, 1, 115-124.	1.2	13
718	Coupled changes in hippocampal structure and cognitive ability in later life. Brain and Behavior, 2018, 8, e00838.	1.0	21
719	Verapamil Inhibits Ser202/Thr205 Phosphorylation of Tau by Blocking TXNIP/ROS/p38 MAPK Pathway. Pharmaceutical Research, 2018, 35, 44.	1.7	50
720	Psychological Stress and Mitochondria: A Conceptual Framework. Psychosomatic Medicine, 2018, 80, 126-140.	1.3	159
721	Coronal CT is Comparable to MR Imaging in Aiding Diagnosis of Dementia in a Memory Clinic in Singapore. Alzheimer Disease and Associated Disorders, 2018, 32, 94-100.	0.6	6
722	A preclinical perspective on the enhanced vulnerability to Alzheimer's disease after early-life stress. Neurobiology of Stress, 2018, 8, 172-185.	1.9	45
723	Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies. Molecular Psychiatry, 2018, 23, 1521-1529.	4.1	58
724	The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [18F]ASEM. NeuroImage, 2018, 165, 118-124.	2.1	27
725	Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts. PLoS Medicine, 2018, 15, e1002647.	3.9	42
727	Diffuse Amyloid-β Plaques, Neurofibrillary Tangles, and the Impact of APOE in Elderly Persons' Brains Lacking Neuritic Amyloid Plaques. Journal of Alzheimer's Disease, 2018, 64, 1307-1324.	1.2	34
728	Metabolite Profile of Alzheimer's Disease in the Frontal Cortex as Analyzed by HRMAS 1H NMR. Frontiers in Aging Neuroscience, 2018, 10, 424.	1.7	12
729	The Neuropathological and Clinical Diagnostic Criteria of Chronic Traumatic Encephalopathy: A Critical Examination in Relation to Other Neurodegenerative Diseases. Journal of Alzheimer's Disease, 2019, 68, 591-608.	1.2	7
730	Late Effects. , 2019, , 496-554.		0
731	Post-Mortem MRI and Histopathology in Neurologic Disease: A Translational Approach. Neuroscience Bulletin, 2019, 35, 229-243.	1.5	18
732	Neuropathological Diagnoses of Demented Hispanic, Black, and Non-Hispanic White Decedents Seen at an Alzheimer's Disease Center. Journal of Alzheimer's Disease, 2019, 68, 145-158.	1.2	56

#	Article	IF	CITATIONS
733	Influence of self-referential mode on memory for aMCI patients. Cognitive Neuropsychology, 2020, 37, 46-57.	0.4	5
734	Molecular imaging in biology and pharmacology. , 2020, , 523-560.		0
735	Late-onset vs nonmendelian early-onset Alzheimer disease. Neurology: Genetics, 2020, 6, e512.	0.9	82
736	Intranasal Insulin as Promising Therapy for Preserving Pragmatic Competence in MCI and AD. , 2020, , .		0
737	Association of serial position scores on memory tests and hippocampal-related neuropathologic outcomes. Neurology, 2020, 95, e3303-e3312.	1.5	9
738	Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies. Neurology, 2020, 94, e2076-e2087.	1.5	42
739	Relationships between amyloid levels, glucose metabolism, morphologic changes in the brain and clinical status of patients with Alzheimer's disease. Annals of Nuclear Medicine, 2020, 34, 337-348.	1.2	13
740	Hippocampal atrophy based Alzheimer's disease diagnosis via machine learning methods. Journal of Neuroscience Methods, 2020, 337, 108669.	1.3	59
741	Lifetime cumulative incidence of dementia in a community-dwelling elderly population in Japan. Neurology, 2020, 95, e508-e518.	1.5	10
742	Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. The Cochrane Library, 2020, 3, CD009628.	1.5	67
743	Clinical trials of new drugs for Alzheimer disease. Journal of Biomedical Science, 2020, 27, 18.	2.6	453
744	Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study. Journal of Alzheimer's Disease, 2020, 75, 751-765.	1.2	10
745	Principal-Component Analysis–Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes. Journal of Nuclear Medicine, 2021, 62, 855-860.	2.8	6
748	Effect of self-imagination on memory for older adults and aMCI patients. Aging, Neuropsychology, and Cognition, 2021, , 1-16.	0.7	1
749	Age-at-Onset and <i>APOE</i> -Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease. Neurology, 2021, 96, e2272-e2283.	1.5	15
750	An Overview of ICA/BSS-Based Application to Alzheimer's Brain Signal Processing. Biomedicines, 2021, 9, 386.	1.4	5
751	Imaging Genetics Study Based on a Temporal Group Sparse Regression and Additive Model for Biomarker Detection of Alzheimer's Disease. IEEE Transactions on Medical Imaging, 2021, 40, 1461-1473.	5.4	14
752	Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer's disease. Japanese Journal of Radiology, 2021, 39, 984-993.	1.0	4

	Сіта	tion Report	
# 753	ARTICLE Cognitive Activity and Onset Age of Incident Alzheimer Disease Dementia. Neurology, 2021, 97,	IF 1.5	Citations
754	e922-e929. Cortical Correlates of Impulsive Aggressive Behavior in Pediatric Bipolar Disorder. Frontiers in Psychiatry, 2021, 12, 674707.	1.3	7
755	Data-Driven vs Consensus Diagnosis of MCI. Neurology, 2021, 97, e1288-e1299.	1.5	12
756	Quercetin. , 2021, , 109-115.		0
757	Kognitive Störungen: Koma, Delir, Demenz. , 2006, , 221-295.		8
758	The Brain on Stress: The Good and the Bad. , 2014, , 1-18.		1
759	Prediction of Memory Impairment with MRI Data: A Longitudinal Study of Alzheimer's Disease. Lectu Notes in Computer Science, 2016, 9900, 273-281.	re 1.0	13
760	Klinische Aspekte der Alzheimer-Krankheit. , 1999, , 71-103.		4
761	The role of biological markers in the early and differential diagnosis of Alzheimer's disease. Journal of Neural Transmission Supplementum, 2002, , 127-133.	0.5	10
762	The prognosis of mild cognitive impairment in the elderly. Journal of Neural Transmission Supplementum, 1998, 54, 31-50.	0.5	90
763	Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. Neurotherapeutics, 2005, 2, 348-360.	2.1	1
764	Glucocorticoids and the Aging Brain: Cause or Consequence?. , 2001, , 883-905.		6
765	Perceptual and memory inhibition deficits in clinically healthy older adults are associated with region-specific, doubly dissociable patterns of cortical thinning Behavioral Neuroscience, 2017, 131, 220-225.	0.6	6
766	20 Brain Imaging in the Evaluation of Putative Alzheimer's Disease-Slowing, Risk-Reducing and Prevention Therapies. , 2009, , 319-350.		10
767	Soluble amyloid beta levels are elevated in the white matter of Alzheimer¿s patients, independent of cortical plaque severity. Acta Neuropathologica Communications, 2014, 2, 83.	2.4	33
769	Alzheimer Disease. CONTINUUM Lifelong Learning in Neurology, 2016, 22, 419-434.	0.4	115
770	The search for disease modification in moderate to severe Alzheimer disease. Neurology, 2005, 65, .	1.5	5
771	Perceived Stress Is Differentially Related to Hippocampal Subfield Volumes among Older Adults. PLoS ONE, 2016, 11, e0154530.	1.1	48

#	Article	IF	CITATIONS
772	Quantifying cognitive resilience in Alzheimer's Disease: The Alzheimer's Disease Cognitive Resilience Score. PLoS ONE, 2020, 15, e0241707.	1.1	18
773	Selectively Reduced Expression of Synaptic Plasticity-Related Genes in Amyloid Precursor Protein + Presenilin-1 Transgenic Mice. Journal of Neuroscience, 2003, 23, 5219-5226.	1.7	223
774	Quality of Education and Memory Test Performance in Older Men: The New York University Paragraph Recall Test Normative Data. Current Alzheimer Research, 2013, 10, 776-783.	0.7	7
775	Positron emission tomography in Alzheimer's disease: early prediction and differentiation. Future Neurology, 2009, 4, 23-38.	0.9	1
776	RELATIONSHIP BETWEEN DISCRIMINATION TASKS OF THE CANTAB AND THE CORPUS CALLOSUM MORPHOLOGY IN ALZHEIMER'S DISEASE. Perceptual and Motor Skills, 2001, 92, 1205.	0.6	1
778	Clinical Aspects of Alzheimer's Disease. , 2001, , 1157-1177.		0
779	Dementias. , 2003, , 199-242.		0
780	Predicting Progression of Alzheimer's Disease With Magnetic Resonance. , 2005, , 95-105.		0
782	Neurodegenerative disorders. , 2007, , 395-412.		0
784	Imaging CNS Disease States: Alzheimer's Disease. , 2010, , 303-318.		0
786	Neuroimage Classification for Early Diagnosis of Alzheimer's Disease. Advances in Bioinformatics and Biomedical Engineering Book Series, 2012, , 336-350.	0.2	0
787	Role of Cellular Prion Protein in the Amyloid-β Oligomer Pathophysiology of Alzheimer's Disease. , 2013, , 35-48.		0
788	Biochemische und genetische Möglichkeiten zur Früherkennung der Alzheimer-Krankheit. , 1998, , 243-249.		0
789	New Frontiers in Alzheimer's Disease Diagnosis. , 0, , .		0
790	Association of mental health, obesity and arterial hypertension. Cardiologia Croatica, 2017, 12, 325-329.	0.0	0
793	Neurobiological Basis of Childhood Trauma and the Risk for Neurological Deficits Later in Life. , 2020, , 385-410.		2
795	Quantitative magnetic resonance techniques as surrogate markers of Alzheimer's disease. Neurotherapeutics, 2004, 1, 196-205.	2.1	0
799	A quantitative MR study of the hippocampal formation, the amygdala, and the temporal horn of the lateral ventricle in healthy subjects 40 to 90 years of age. American Journal of Neuroradiology, 1999, 20, 207-11.	1.2	145

ARTICLE IF CITATIONS Temporal horn index and volume of medial temporal lobe atrophy using a new semiautomated method 800 1.2 24 for rapid and precise assessment. American Journal of Neuroradiology, 2006, 27, 1454-8. Hippocampal cerebrospinal fluid spaces on MR imaging: Relationship to aging and Alzheimer disease. 1.2 24 American Journal of Neuroradiology, 2006, 27, 912-8. Hippocampal atrophy confounds template-based functional MR imaging measures of hippocampal 802 activation in patients with mild cognitive impairment. American Journal of Neuroradiology, 2006, 27, 1.2 22 1622-7. Correlates of Conversion from Mild Cognitive Impairment to Dementia with Lewy Bodies: Data from 1.2 the National Alzheimer's Coordinating Center. Journal of Alzheimer's Disease, 2022, 86, 1643-1654. Targeted Metabolomic Analysis in Alzheimer's Disease Plasma and Brain Tissue in Non-Hispanic Whites. 804 1.2 17 Journal of Alzheimer's Disease, 2022, 86, 1875-1895. The association of basal cortisol levels with episodic memory in older adults is mediated by executive function. Neurobiology of Learning and Memory, 2022, 190, 107600. 1.0 Structure-constrained combination-based nonlinear association analysis between incomplete multimodal imaging and genetic data for biomarker detection of neurodegenerative diseases. Medical Image Analysis, 2022, 78, 102419. 806 7.0 5 Lipid Peroxidation Induced ApoE Receptor-Ligand Disruption as a Unifying Hypothesis Underlying 1.2 Sporadic Alzheimer's Disease in Humans. Journal of Alzheimer's Disease, 2022, 87, 1251-1290. Latent learning in medial temporal amnesia: evidence for disrupted representational but preserved 808 1.0 3 attentional processes. Neuropsychology, 2000, 14, 3-15. Seronegative autoimmune encephalitis: clinical characteristics and factors associated with 809 outcomes. Brain, 2022, 145, 3509-3521. Data-Driven Analyses of Longitudinal Hippocampal Imaging Trajectories: Discrimination and Biomarker 810 1.2 1 Prediction of Change Classes. Journal of Alzheimer's Disease, 2022, , 1-19. Neuropathology and cholinesterase expression in the brains of octogenarians and older. 814 Chemico-Biological Interactions, 2022, 364, 110065. Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy 815 1.5 2 Bodies or Alzheimer Disease. Neurology, 2022, 99, . MOG antibody-associated encephalitis in adult: clinical phenotypes and outcomes. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 102-112. Cannabinoids in neuroinflammatory disorders: Focusing on multiple sclerosis, Parkinsons, and 820 2.6 13 Alzheimers diseases. BioFactors, 2023, 49, 560-583. SUFI: an automated approach to spectral unmixing of fluorescent multiplex images captured in mouse and post-mortem human brain tissues. BMC Neuroscience, 2023, 24, . Default mode network failure and neurodegeneration across aging and amnestic and dysexecutive 823 1.55 Alzheimer's disease. Brain Communications, 2023, 5, . Relationship between Brain-Derived Neurotrophic Factor and Cognitive Decline in Patients with Mild 824 1.8 Cognitive Impairment and Dementia. Biomolecules, 2023, 13, 570.

#	Article	IF	CITATIONS
825	Apraxia and dementia severity in Alzheimer's disease: a systematic review. Journal of Clinical and Experimental Neuropsychology, 0, , 1-20.	0.8	2